chronic fatigue syndrome: a medical condition characterized by long-term fatigue and other symptoms that limit a person's ability to carry out ordinary daily activities.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
348 |
4. Check minimum number of eventsNone |
348 |
5. Include endpointsNone |
348 |
6. Filter based on genotype QC (FinnGen only) |
334 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Syndroma lassitudinis postvirale
Similar endpoints
↥List of similar endpoints to
Postviral fatigue syndrome
based on the number of shared cases.
Similar with more cases:
- Cerebral cysts
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1622 | 1089 | 525 |
| Only index persons | 1588 | 1074 | 514 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 34.76 | 35.80 | 32.61 |
| Only index persons | 34.81 | 35.74 | 32.86 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 334 | 266 | 68 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.03 |
| Median age at first event (years) | 39.94 | 40.16 | 39.09 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 348
- Matched controls
- 3480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.3
ICD-10 Finland
Postviral fatigue syndrome
+∞
307.7
348
8
R53
ICD-10 Finland
Malaise and fatigue
10.8
108.0
245
627
R68.88
ICD-10 Finland
Other specified general symptoms and signs, not elsewhere classified.
35.0
78.6
51
17
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
9.0
62.5
90
130
N06AX21
ATC
duloxetine; oral
6.5
55.9
119
259
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
10.5
55.4
67
77
N06AX12
ATC
bupropion; oral
6.6
55.0
111
229
U09.9
ICD-10 Finland
Post COVID-19 condition, unspecified
25.7
54.4
39
17
M79.7
ICD-10 Finland
Fibromyalgia
10.5
52.2
63
72
A04
ICPC
Weakness/tiredness general
5.6
51.9
140
375
N06AX16
ATC
venlafaxine; oral
5.6
51.4
137
363
N04BC05
ATC
pramipexole; oral
9.3
47.5
63
81
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.5
46.2
118
298
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
8.1
44.1
66
98
TAB00
NOMESCO Finland
Lumbar puncture
9.0
43.9
59
77
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
8.7
42.0
58
78
F48.0
ICD-10 Finland
Neurasthenia
238.0
41.9
42
*
M35.7
ICD-10 Finland
Hypermobility syndrome
13.5
41.8
41
34
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
6.7
41.3
75
137
Z01.8
ICD-10 Finland
Other specified special examinations
4.6
41.2
142
453
XA800
NOMESCO Finland
Neuropsychological investigation
7.9
36.8
55
81
N03AX12
ATC
[U] gabapentin; oral
4.8
35.0
97
257
G47.3
ICD-10 Finland
Sleep apnoea
4.3
34.3
119
375
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
8.7
34.0
46
60
C07AB07
ATC
bisoprolol; oral
3.9
33.5
160
629
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
5.4
32.0
72
159
L28
ICPC
Limited function/disability (L)
4.9
31.8
84
213
A28
ICPC
Limited function/disability NOS
6.1
31.3
61
118
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.2
30.4
43
59
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
5.7
29.9
63
131
R42
ICD-10 Finland
Dizziness and giddiness
4.1
29.3
104
329
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.0
29.0
73
177
N03AX16
ATC
[U] pregabalin
3.9
29.0
112
376
R4110
NOMESCO Finland
Physiotherapy
3.6
28.2
133
509
R50.9
ICD-10 Finland
Fever, unspecified
3.9
27.8
104
340
R51.80
ICD-10 Finland
Headache
3.6
27.5
127
478
R03DC03
ATC
montelukast; oral
3.7
27.3
115
407
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
8.0
27.3
39
54
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
7.3
27.0
42
64
H02AB09
ATC
hydrocortisone; systemic
11.2
26.6
29
28
N06AX26
ATC
vortioxetine; oral
4.4
25.8
75
203
G90.8
ICD-10 Finland
Other disorders of autonomic nervous system
+∞
25.3
24
*
N06AX11
ATC
mirtazapine; oral
3.2
25.1
177
853
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
9.4
24.9
31
36
C07AA05
ATC
propranolol; systemic
3.3
24.7
134
552
M79.0
ICD-10 Finland
Rheumatism, unspecified
8.6
24.7
33
42
Q79.6
ICD-10 Finland
Ehlers-Danlos syndrome
58.3
23.4
27
5
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.5
23.3
103
372
N04BC09
ATC
rotigotine; transdermal
70.0
23.2
26
*
R06.0
ICD-10 Finland
Dyspnoea
3.3
23.0
123
500
H02AB06
ATC
prednisolone; systemic
3.0
22.5
196
1046
XF404
NOMESCO Finland
Ambulatory ECG
6.5
22.2
38
64
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
5.0
22.1
52
118
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
22.0
115
459
G43.3
ICD-10 Finland
Complicated migraine
7.1
21.7
34
52
N05BA04
ATC
oxazepam; oral
3.1
21.7
135
596
ZY010
NOMESCO Finland
Hospital outpatient
4.6
21.6
57
142
N06AX22
ATC
agomelatine; oral
6.8
21.4
35
56
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
5.6
21.3
43
85
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
21.1
156
754
N06AB04
ATC
citalopram; systemic
3.2
21.0
107
419
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
222.8
20.8
21
*
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
4.8
20.5
51
121
A01
ICPC
Pain general/multiple sites
4.2
20.4
62
172
N05AH04
ATC
quetiapine; oral
3.1
20.4
119
504
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
4.1
20.2
63
178
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
7.1
19.9
31
47
A02BA02
ATC
ranitidine; systemic
3.7
19.7
74
238
Z2445
NOMESCO Finland
Psychologist
5.0
19.3
45
101
G43.9
ICD-10 Finland
Migraine, unspecified
3.7
19.2
70
221
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.6
19.1
38
74
A02BC05
ATC
esomeprazole; systemic
2.8
19.0
166
865
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
18.8
55
148
H03AA01
ATC
levothyroxine sodium; systemic
2.9
18.7
117
511
N02BF02
ATC
pregabalin; oral
4.8
18.7
46
108
C01CA24
ATC
epinephrine; parenteral
4.0
18.6
58
164
N06BA07
ATC
modafinil; oral
46.7
18.5
22
5
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.0
18.3
42
93
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.0
18.2
58
166
F32.1
ICD-10 Finland
Moderate depressive episode
3.6
18.0
68
219
Z2446
NOMESCO Finland
Social worker
4.4
17.9
49
125
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.3
17.6
78
278
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.5
17.4
71
240
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
4.0
17.0
53
149
N06CA01
ATC
amitriptyline and psycholeptics; systemic
4.1
16.8
51
141
UJF30
NOMESCO Finland
Ileoscopy through colon
3.9
16.7
54
156
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
4.2
16.7
49
132
R03AC02
ATC
salbutamol; inhalant
2.8
16.6
248
1646
XF402
NOMESCO Finland
ECG with work load test
5.4
16.6
34
68
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.6
16.5
151
792
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.5
16.5
64
209
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
16.5
46
119
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
5.7
16.4
32
61
A02BC02
ATC
pantoprazole; systemic
2.7
16.3
246
1635
R00.2
ICD-10 Finland
Palpitations
3.6
16.1
61
196
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.8
16.1
111
505
R00.0
ICD-10 Finland
Tachycardia, unspecified
5.0
15.8
36
79
J45.9
ICD-10 Finland
Asthma, unspecified
2.9
15.7
89
364
B03BA03
ATC
hydroxocobalamin; parenteral
6.6
15.7
26
42
N03AX11
ATC
topiramate; oral
5.4
15.6
32
64
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
12.1
15.6
28
25
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.1
15.6
75
280
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
4.3
15.5
43
111
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
3.3
15.3
66
230
A03FA01
ATC
metoclopramide; systemic, rectal
2.8
15.3
100
441
N06AG02
ATC
moclobemide; oral
6.1
15.2
27
47
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
15.0
33
70
N06BA04
ATC
methylphenidate; oral
3.7
14.9
52
158
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
14.6
64
225
F41.1
ICD-10 Finland
Generalized anxiety disorder
3.3
14.6
62
214
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.3
14.5
25
42
N06AB03
ATC
fluoxetine; oral
3.2
14.5
66
238
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.5
14.5
55
177
XQ800
NOMESCO Finland
Prick test
3.6
14.2
52
163
K30
ICD-10 Finland
Functional dyspepsia
3.1
14.1
66
241
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.4
14.1
177
1054
N17
ICPC
Vertigo/dizziness
3.3
14.0
60
208
F43.1
ICD-10 Finland
Post-traumatic stress disorder
4.2
13.9
39
101
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.7
13.7
95
429
N06AB06
ATC
sertraline; oral
2.8
13.7
81
338
R52.2
ICD-10 Finland
Other chronic pain
5.2
13.6
29
60
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.2
13.6
29
60
R52.9
ICD-10 Finland
Pain, unspecified
3.3
13.5
58
201
N04BD01
ATC
selegiline; oral
27.0
13.5
18
7
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.9
13.3
41
114
R11
ICD-10 Finland
Nausea and vomiting
3.3
13.3
56
192
SPAT1229
SPAT
Assessment of need for aid
6.2
13.2
23
39
F34.1
ICD-10 Finland
Dysthymia
4.4
13.2
35
87
M79.1
ICD-10 Finland
Myalgia
2.6
13.0
92
419
N06AA09
ATC
amitriptyline; systemic
3.9
13.0
40
111
R5140
NOMESCO Finland
Monitoring the use of the aid
3.6
12.8
45
137
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
6.3
12.8
22
37
Z02.7
ICD-10 Finland
Issue of medical certificate
3.5
12.7
47
148
M03BX01
ATC
baclofen; systemic
10.7
12.7
24
24
G43.8
ICD-10 Finland
Other migraine
5.9
12.6
23
41
N06AB10
ATC
escitalopram; oral
2.4
12.6
124
658
G44.2
ICD-10 Finland
Tension-type headache
2.6
12.5
86
386
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
5.7
12.5
24
45
N03AE01
ATC
clonazepam; systemic
4.6
12.5
31
73
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.6
12.5
31
73
M54.2
ICD-10 Finland
Cervicalgia
3.2
12.4
55
194
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
3.9
12.4
38
105
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
4.2
12.4
35
91
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.6
12.4
87
394
XKD00
NOMESCO Finland
Uroflowmetry
4.8
12.4
29
65
N02AX02
ATC
tramadol; systemic, rectal
2.3
12.4
148
852
R20.2
ICD-10 Finland
Paraesthesia of skin
3.4
12.2
48
157
R4120
NOMESCO Finland
Occupational therapy
3.8
12.2
39
111
R96
ICPC
Asthma
3.5
12.2
46
147
N28
ICPC
Limited function/disability (N)
22.2
12.1
17
8
3007
Kela drug reimbursment
Erenumab and fremanezumab
6.0
12.1
22
39
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
6.0
12.1
22
39
F51.0
ICD-10 Finland
Nonorganic insomnia
2.4
11.9
113
587
R03BA08
ATC
ciclesonide; inhalant
3.3
11.8
49
166
J01MA02
ATC
ciprofloxacin; systemic
2.3
11.7
126
691
OAB93, ,
SPAT
2.9
11.6
60
231
G47.8
ICD-10 Finland
Other sleep disorders
5.1
11.6
25
52
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.8
11.5
65
263
Z71.8
ICD-10 Finland
Other specified counselling
2.2
11.5
168
1041
SHB00
NOMESCO Finland
Preparing and fitting the occlusal splint in the mouth
2.5
11.4
83
382
N05CF02
ATC
zolpidem; oral
2.6
11.3
80
362
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
11.3
63
253
IGY99
NOMESCO Finland
Other psychiatric treatment contact
4.5
11.2
28
66
Z3231
NOMESCO Finland
Registered nurse
2.3
11.2
110
578
J01FA09
ATC
clarithromycin; systemic
2.2
11.2
139
806
AA1BG, ,
SPAT
6.0
11.1
20
35
Z3226
NOMESCO Finland
Physiotherapist
2.6
11.1
74
325
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.8
11.1
65
268
M25.5
ICD-10 Finland
Pain in joint
2.2
11.0
152
918
J31.0
ICD-10 Finland
Chronic rhinitis
2.9
10.9
56
215
I49.9
ICD-10 Finland
Cardiac arrhythmia, unspecified
2.7
10.9
67
283
H02AA02
ATC
fludrocortisone; oral
61.9
10.7
12
*
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
11.7
10.7
19
17
F60.5
ICD-10 Finland
Anankastic personality disorder
11.7
10.7
19
17
IBA04
NOMESCO Finland
Extensive initial psychiatric evaluation
5.3
10.7
22
44
R13
ICD-10 Finland
Dysphagia
4.1
10.6
30
78
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
2.4
10.6
86
415
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.0
10.6
50
183
AA1AD
NOMESCO Finland
CT of head and brain
2.5
10.5
75
340
N02CC03
ATC
zolmitriptan; nasal, oral
3.2
10.5
45
155
J01AA02
ATC
doxycycline; systemic
2.4
10.5
267
2027
R4110, ,
SPAT
2.9
10.4
53
202
U09
ICD-10 Finland
Post COVID-19 condition
11.1
10.4
19
18
K58.9
ICD-10 Finland
Irritable bowel syndrome without diarrhoea
5.0
10.4
23
49
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.9
10.3
54
209
N02BF01
ATC
gabapentin; oral
3.0
10.3
49
180
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
4.0
10.3
30
80
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
3.9
10.2
31
85
R03BA05
ATC
fluticasone; inhalant
2.4
10.2
88
436
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
10.5
10.1
19
19
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.1
10.1
133
781
K07.60
ICD-10 Finland
Snapping jaw
3.1
10.1
44
153
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
15.2
10.1
16
11
R02
ICPC
Shortness of breath/dyspnoea
2.8
10.0
55
219
R4190
NOMESCO Finland
Nutritional therapy
3.9
9.9
30
82
WX723
NOMESCO Finland
CPAP therapy
4.8
9.9
23
51
N05AB03
ATC
perphenazine; systemic, rectal
5.1
9.9
21
43
N07AA02
ATC
pyridostigmine; systemic
20.8
9.9
14
7
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.7
75
352
G44.8
ICD-10 Finland
Other specified headache syndromes
8.8
9.7
20
24
G50.1
ICD-10 Finland
Atypical facial pain
10.5
9.6
18
18
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
4.3
9.6
25
61
N06AX03
ATC
mianserin; oral
4.3
9.6
25
61
UJF32
NOMESCO Finland
Coloscopy
2.4
9.6
75
354
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
9.5
98
521
R06AE07
ATC
cetirizine; oral
2.0
9.5
188
1276
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
4.2
9.5
26
66
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
5.4
9.5
19
37
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
31.0
9.5
12
*
N05CF01
ATC
zopiclone; oral
2.2
9.4
106
584
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
4.1
9.3
26
67
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
9.3
88
451
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
3.6
9.3
31
91
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
3.6
9.3
32
96
G47.9
ICD-10 Finland
Sleep disorder, unspecified
4.2
9.2
25
63
F33.1
ICD-10 Finland
Recurrent depressive disorder, current episode moderate
3.5
9.1
32
97
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.3
9.1
80
397
G54.0
ICD-10 Finland
Brachial plexus disorders
4.4
9.1
23
55
T78.4
ICD-10 Finland
Allergy, unspecified
3.6
9.0
31
93
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
8.8
137
849
ZXY01
NOMESCO Finland
Chief Physician, Head of Department or Deputy Chief Physician
8.0
8.8
19
25
Z01.9
ICD-10 Finland
Special examination, unspecified
3.5
8.7
31
95
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.3
8.7
82
419
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
12.0
8.7
15
13
P29
ICPC
Psychological sympt/compl other
2.5
8.6
61
274
R01AD05
ATC
budesonide; nasal
3.1
8.6
38
133
ZYC01
NOMESCO Finland
Remote contact by phone
3.2
8.6
36
122
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
8.6
85
442
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.6
8.6
29
86
M01AH01
ATC
celecoxib; oral
2.6
8.5
54
230
L19
ICPC
Muscle symptom/complaint NOS
4.5
8.5
21
49
M03BC01
ATC
orphenadrine (citrate); systemic
2.1
8.5
105
596
N05BA01
ATC
diazepam; systemic, rectal
2.7
8.5
48
193
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
8.5
144
916
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.6
8.5
51
212
R06.5
ICD-10 Finland
Mouth breathing
2.9
8.4
41
152
F41.09
ICD-10 Finland
UNS Panic Syndrome
3.7
8.4
27
77
SPAT1216
SPAT
Assessment of functional ability
3.0
8.3
38
136
R51.81
ICD-10 Finland
Facial pain NOS
6.8
8.3
20
31
M01AE02
ATC
naproxen; oral, rectal
2.0
8.3
229
1714
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.6
8.3
20
46
C09CA06
ATC
candesartan; oral
2.2
8.2
84
442
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
8.2
86
458
K59.09
ICD-10 Finland
Constipation, unspecified
3.8
8.2
25
69
R07.0
ICD-10 Finland
Pain in throat
2.7
8.2
48
197
D01
ICPC
Abdominal pain/cramps general
2.3
8.2
69
336
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
17.7
8.1
12
7
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
9.3
8.1
16
18
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.2
8.1
74
373
J45.1
ICD-10 Finland
Nonallergic asthma
3.3
8.0
31
100
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.9
8.0
158
1052
N03AX09
ATC
lamotrigine; oral
3.0
8.0
37
133
N02CC05
ATC
almotriptan; oral
3.2
8.0
33
111
N06AX05
ATC
trazodone; oral
6.4
8.0
20
33
R06AX13
ATC
loratadine; oral
2.2
8.0
76
389
R01AD12
ATC
fluticasone furoate; nasal
1.9
8.0
154
1019
Z2221
NOMESCO Finland
Medical doctor
2.0
7.9
118
714
IBA01, ,
SPAT
4.2
7.9
21
52
U08.9
ICD-10 Finland
Personal history of COVID-19, unspecified
11.2
7.9
14
13
P01
ICPC
Feeling anxious/nervous/tense
2.1
7.8
98
557
N92.6
ICD-10 Finland
Irregular menstruation, unspecified
2.5
7.8
52
227
S13.4
ICD-10 Finland
Sprain and strain of cervical spine
3.2
7.8
31
102
F41.8
ICD-10 Finland
Other specified anxiety disorders
3.2
7.8
31
102
LCA06
NOMESCO Finland
Biopsy of endometrium
2.3
7.8
63
301
A11
ICPC
Chest pain NOS
3.3
7.7
29
92
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
3.8
7.7
24
67
M01AC06
ATC
meloxicam; systemic, rectal
2.0
7.7
110
655
A29
ICPC
General symptom/complaint other
2.5
7.7
53
235
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
3.6
7.7
26
77
F33.00
ICD-10 Finland
Recurrent depression, mild episode without somatic syndrome
4.0
7.6
22
58
N99
ICPC
Neurological disease other
18.9
7.6
11
6
J02AC01
ATC
fluconazole; systemic
1.9
7.6
175
1219
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
9.2
7.6
15
17
A02BA03
ATC
famotidine; systemic
10.4
7.6
14
14
R06AX26
ATC
fexofenadine; oral
2.7
7.6
43
173
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
7.6
127
798
R03AK11
ATC
formoterol and fluticasone; inhalant
6.7
7.5
18
28
Z3229
NOMESCO Finland
Other healthcare associate professional
3.2
7.5
30
99
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.3
7.4
28
89
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
13.8
7.4
12
9
K59.1
ICD-10 Finland
Functional diarrhoea
3.6
7.4
25
74
G44.0
ICD-10 Finland
Cluster headache syndrome
7.1
7.4
17
25
N05BE01
ATC
buspirone; oral
4.3
7.4
19
46
N80.0
ICD-10 Finland
Endometriosis of uterus
4.3
7.4
19
46
P03
ICPC
Feeling depressed
2.2
7.4
74
386
E61.1
ICD-10 Finland
Iron deficiency
3.2
7.3
29
95
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
7.3
7
*
I49.8
ICD-10 Finland
Other specified cardiac arrhythmias
4.5
7.3
18
42
J45
ICD-10 Finland
Asthma
2.5
7.3
50
221
P76
ICPC
Depressive disorder
2.5
7.3
50
221
N06AB05
ATC
paroxetine; oral
3.0
7.3
32
112
F51.9
ICD-10 Finland
Nonorganic sleep disorder, unspecified
4.1
7.3
20
51
A02BC04
ATC
rabeprazole; oral
2.6
7.3
43
177
C10AC01
ATC
colestyramine; oral
4.7
7.3
17
38
G04CA01
ATC
alfuzosin; oral
4.7
7.3
17
38
P01AB01
ATC
metronidazole; oral, rectal
1.9
7.2
153
1034
NXL00
NOMESCO Finland
Biopsy of muscle
30.7
7.2
9
*
L99
ICPC
Musculoskeletal disease other
5.8
7.2
19
34
JN3AD
NOMESCO Finland
Abdominal CT examination
2.6
7.1
45
191
Z31.5
ICD-10 Finland
Genetic counselling
2.8
7.1
38
148
F33.01
ICD-10 Finland
Recurrent depression, mild episode of somatic syndrome
12.4
7.1
12
10
SPAT1301
SPAT
No procedures
2.0
7.1
105
630
M47.80
ICD-10 Finland
Other spondylosis, multiple sites in spine
9.1
7.1
14
16
N05AX12
ATC
aripiprazole; systemic
2.9
7.1
35
131
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.7
7.1
39
155
M79.6
ICD-10 Finland
Pain in limb
1.8
7.0
165
1148
IGY02
NOMESCO Finland
Psychiatric monitoring contact
3.1
7.0
30
103
M54.5
ICD-10 Finland
Low back pain
1.8
7.0
150
1014
N94.1
ICD-10 Finland
Dyspareunia
6.6
7.0
17
27
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
6.1
7.0
18
31
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.6
7.0
42
174
E0000UV, ,
ATC
1.8
7.0
160
1106
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.1
6.9
30
104
SHA03
NOMESCO Finland
Stomatognathic treatment, demanding
3.3
6.9
26
83
R4120, ,
SPAT
11.2
6.8
12
11
R29
ICPC
Respiratory symptom/complaint other
2.7
6.8
38
152
R05
ICD-10 Finland
Cough
2.0
6.8
85
481
A03
ICPC
Fever
2.0
6.8
93
544
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.9
6.7
32
117
R01AD08
ATC
fluticasone; nasal
1.9
6.7
122
781
J05AB11
ATC
valaciclovir; oral
2.2
6.7
62
312
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.6
6.7
39
159
IBZ02
NOMESCO Finland
Somatic assessment of psychiatric patient
23.0
6.7
9
*
T91
ICPC
Vitamin/nutritional deficiency
23.0
6.7
9
*
F33
ICD-10 Finland
Recurrent depressive disorder
3.7
6.7
21
59
H53.2
ICD-10 Finland
Diplopia
6.1
6.7
17
29
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
2.4
6.7
46
204
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.2
6.7
27
90
N06BA12
ATC
lisdexamfetamine; oral
4.0
6.6
19
50
ZX120
NOMESCO Finland
Intravenous
2.8
6.6
34
130
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
9.0
6.6
13
15
N29
ICPC
Neurological sympt/complt other
7.1
6.6
15
22
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
7.1
6.6
15
22
N06AX17
ATC
milnacipran; oral
10.3
6.6
12
12
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.4
6.6
24
75
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.2
6.5
60
301
UJF92
NOMESCO Finland
Capsular endoscopy
5.9
6.5
17
30
R06AX22
ATC
ebastine; oral
2.0
6.5
81
457
F33.4
ICD-10 Finland
Recurrent depressive disorder, currently in remission
3.2
6.5
25
81
R51
ICD-10 Finland
Headache
2.6
6.4
38
156
ICB07, ,
NOMESCO Finland
71.1
6.4
7
*
A02BC01
ATC
omeprazole; systemic
2.0
6.4
86
497
R21
ICPC
Throat symptom/complaint
1.8
6.4
131
868
N02CD03
ATC
fremanezumab; systemic
5.7
6.4
17
31
M03AX01
ATC
botulinum toxin; parenteral
6.2
6.4
16
27
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
2.1
6.4
68
362
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
3.0
6.4
28
98
A07AA02
ATC
nystatin; oral
4.0
6.3
18
47
F29
ICPC
Eye symptom/complaint other
2.3
6.3
48
222
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
3.1
6.3
27
93
R68.81
ICD-10 Finland
A constant or recurrent sensitivity to experience symptoms and signs in relation to common factors in the environment, not elsewhere classified.
18.4
6.3
9
5
P99
ICPC
Psychological disorders other
3.3
6.3
24
77
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
7.2
6.3
14
20
N89
ICPC
Migraine
2.7
6.3
35
140
H02
ICPC
Hearing complaint
2.7
6.2
34
134
R03AC12
ATC
salmeterol; inhalant
4.1
6.2
17
43
F90.0
ICD-10 Finland
Disturbance of activity and attention
2.5
6.2
42
184
OAA68, ,
SPAT
5.9
6.2
16
28
A04AA01
ATC
ondansetron; systemic, rectal
2.8
6.2
31
117
D09
ICPC
Nausea
2.7
6.2
34
135
R33
ICD-10 Finland
Retention of urine
4.3
6.2
16
39
J01FF01
ATC
clindamycin; systemic
1.9
6.1
93
560
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
3.7
6.1
19
53
N06AX18
ATC
reboxetine; oral
12.8
6.1
10
8
A99
ICPC
Disease/condition unspecnature/site
2.5
6.1
40
173
R06.4
ICD-10 Finland
Hyperventilation
6.9
6.1
14
21
N06AA10
ATC
nortriptyline; systemic
5.4
6.1
17
33
S01GX01
ATC
cromoglicic acid; ophthalmic
1.9
6.1
101
626
R69
ICD-10 Finland
Unknown and unspecified causes of morbidity
6.2
6.1
15
25
M01AE03
ATC
ketoprofen; systemic, rectal
1.9
6.0
103
644
A02BC03
ATC
lansoprazole; oral
1.9
6.0
84
492
H02AB07
ATC
prednisone; oral
2.3
6.0
45
207
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Malaise and fatigue
R53 [45553741]
R53 [45553741]
2.6e+00
3.3e+00
3.6e+00
—
3.1e+00
2.8e+00
1.9e+00
cases:35.34%
controls:3.85%
cases:35.92%
controls:1.95%
cases:8.91%
controls:0.26%
—
—
cases:6.90%
controls:0.35%
cases:21.24%
controls:1.57%
cases:31.39%
controls:6.56%
123
134
225
3346
125
68
223
3412
31
9
317
3471
—
24
12
324
3463
72
53
267
3325
86
178
188
2536
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
2.7e+00
3.1e+00
3.7e+00
—
3.1e+00
2.5e+00
2.0e+00
cases:23.28%
controls:2.10%
cases:18.10%
controls:1.01%
cases:5.75%
controls:0.14%
—
—
cases:4.89%
controls:0.23%
cases:9.44%
controls:0.83%
cases:18.25%
controls:2.80%
81
73
267
3407
63
35
285
3445
20
5
328
3475
—
17
8
331
3467
32
28
307
3350
50
76
224
2638
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
1.4e+00
2.4e+00
3.6e+00
1.0e+50
4.0e+00
3.2e+00
2.1e+00
cases:24.14%
controls:7.56%
cases:22.70%
controls:2.59%
cases:11.21%
controls:0.34%
cases:15.52%
controls:0.00%
cases:13.51%
controls:0.29%
cases:34.22%
controls:2.10%
cases:37.23%
controls:6.85%
84
263
264
3217
79
90
269
3390
39
12
309
3468
54
0
294
3480
47
10
301
3465
116
71
223
3307
102
186
172
2528
Psychiatry
26 [38004469]
26 [38004469]
1.5e+00
1.8e+00
1.7e+00
4.4e+00
1.9e+00
2.3e+00
2.1e+00
cases:32.47%
controls:9.77%
cases:27.87%
controls:5.80%
cases:12.64%
controls:2.59%
cases:13.79%
controls:0.20%
cases:13.51%
controls:2.30%
cases:37.17%
controls:5.39%
cases:46.35%
controls:9.87%
113
340
235
3140
97
202
251
3278
44
90
304
3390
48
7
300
3473
47
80
301
3395
126
182
213
3196
127
268
147
2446
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
2.0e+00
2.6e+00
3.0e+00
—
3.7e+00
2.1e+00
1.5e+00
cases:28.74%
controls:5.32%
cases:20.11%
controls:1.87%
cases:5.17%
controls:0.26%
—
—
cases:5.46%
controls:0.14%
cases:12.68%
controls:1.72%
cases:20.80%
controls:5.31%
100
185
248
3295
70
65
278
3415
18
9
330
3471
—
19
5
329
3470
43
58
296
3320
57
144
217
2570
Neurology
13 [38004458]
13 [38004458]
2.0e+00
2.7e+00
2.5e+00
—
2.5e+00
2.7e+00
2.3e+00
cases:37.93%
controls:7.84%
cases:35.92%
controls:3.76%
cases:11.49%
controls:1.01%
—
—
cases:10.06%
controls:0.92%
cases:37.46%
controls:3.70%
cases:44.53%
controls:7.41%
132
273
216
3207
125
131
223
3349
40
35
308
3445
—
35
32
313
3443
127
125
212
3253
122
201
152
2513
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
2.0e+00
2.5e+00
3.1e+00
—
2.3e+00
1.9e+00
1.6e+00
cases:11.49%
controls:1.81%
cases:8.05%
controls:0.69%
cases:3.74%
controls:0.17%
—
—
cases:1.72%
controls:0.17%
cases:5.31%
controls:0.86%
cases:9.85%
controls:2.21%
40
63
308
3417
28
24
320
3456
13
6
335
3474
—
6
6
342
3469
18
29
321
3349
27
60
247
2654
duloxetine; oral
N06AX21 [21604749]
N06AX21 [21604749]
1.7e+00
2.2e+00
2.1e+00
—
2.8e+00
2.3e+00
2.0e+00
cases:10.63%
controls:2.16%
cases:6.90%
controls:0.80%
cases:2.01%
controls:0.26%
—
—
cases:3.74%
controls:0.23%
cases:8.55%
controls:0.89%
cases:12.04%
controls:1.84%
37
75
311
3405
24
28
324
3452
7
9
341
3471
—
13
8
335
3467
29
30
310
3348
33
50
241
2664
Complicated migraine
G43.3 [45576576]
G43.3 [45576576]
2.3e+00
3.0e+00
—
1.0e+50
2.9e+00
2.3e+00
2.3e+00
cases:4.02%
controls:0.43%
cases:3.74%
controls:0.20%
—
—
cases:2.01%
controls:0.00%
cases:2.59%
controls:0.14%
cases:2.95%
controls:0.30%
cases:5.84%
controls:0.63%
14
15
334
3465
13
7
335
3473
—
7
0
341
3480
9
5
339
3470
10
10
329
3368
16
17
258
2697
Infectious Disease
44 [38004484]
44 [38004484]
1.8e+00
2.4e+00
3.1e+00
1.0e+50
—
3.1e+00
1.8e+00
cases:11.49%
controls:2.16%
cases:10.92%
controls:1.12%
cases:3.74%
controls:0.17%
cases:19.83%
controls:0.00%
—
—
cases:17.11%
controls:0.95%
cases:12.41%
controls:2.32%
40
75
308
3405
38
39
310
3441
13
6
335
3474
69
0
279
3480
—
58
32
281
3346
34
63
240
2651
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
R29.8 [45587505]
2.6e+00
3.9e+00
—
1.0e+50
—
3.4e+00
1.8e+00
cases:8.33%
controls:0.66%
cases:8.91%
controls:0.20%
—
—
cases:1.72%
controls:0.00%
—
—
cases:5.90%
controls:0.21%
cases:7.30%
controls:1.25%
29
23
319
3457
31
7
317
3473
—
6
0
342
3480
—
20
7
319
3371
20
34
254
2680
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
R41.8 [45534452]
2.6e+00
2.7e+00
—
1.0e+50
—
3.1e+00
2.9e+00
cases:6.61%
controls:0.52%
cases:4.02%
controls:0.29%
—
—
cases:1.44%
controls:0.00%
—
—
cases:3.83%
controls:0.18%
cases:5.47%
controls:0.33%
23
18
325
3462
14
10
334
3470
—
5
0
343
3480
—
13
6
326
3372
15
9
259
2705
Fibromyalgia
M79.7 [45553272]
M79.7 [45553272]
2.6e+00
3.0e+00
1.0e+50
1.0e+50
—
3.0e+00
2.7e+00
cases:8.33%
controls:0.69%
cases:6.90%
controls:0.37%
cases:1.44%
controls:0.00%
cases:4.02%
controls:0.00%
—
—
cases:7.96%
controls:0.44%
cases:11.31%
controls:0.85%
29
24
319
3456
24
13
324
3467
5
0
343
3480
14
0
334
3480
—
27
15
312
3363
31
23
243
2691
Sleep apnoea
G47.3 [45562094]
G47.3 [45562094]
1.5e+00
1.8e+00
2.1e+00
1.0e+50
2.4e+00
2.0e+00
1.4e+00
cases:12.07%
controls:3.10%
cases:11.49%
controls:2.01%
cases:4.89%
controls:0.60%
cases:6.32%
controls:0.00%
cases:6.03%
controls:0.58%
cases:15.04%
controls:2.46%
cases:16.42%
controls:4.68%
42
108
306
3372
40
70
308
3410
17
21
331
3459
22
0
326
3480
21
20
327
3455
51
83
288
3295
45
127
229
2587
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
Z50.8 [45556842]
1.6e+00
3.5e+00
—
1.0e+50
—
3.3e+00
2.8e+00
cases:4.02%
controls:0.83%
cases:5.46%
controls:0.17%
—
—
cases:3.45%
controls:0.00%
—
—
cases:5.90%
controls:0.24%
cases:6.20%
controls:0.41%
14
29
334
3451
19
6
329
3474
—
12
0
336
3480
—
20
8
319
3370
17
11
257
2703
Recurrent depression, moderate episode of somatic syndrome
F33.11 [2000501985]
F33.11 [2000501985]
2.2e+00
2.3e+00
—
1.0e+50
—
3.2e+00
3.2e+00
cases:3.74%
controls:0.43%
cases:1.72%
controls:0.17%
—
—
cases:2.01%
controls:0.00%
—
—
cases:4.13%
controls:0.18%
cases:5.84%
controls:0.26%
13
15
335
3465
6
6
342
3474
—
7
0
341
3480
—
14
6
325
3372
16
7
258
2707
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
F33.2 [45547705]
2.0e+00
1.8e+00
2.5e+00
—
2.0e+00
2.4e+00
2.1e+00
cases:6.32%
controls:0.95%
cases:3.45%
controls:0.60%
cases:1.72%
controls:0.14%
—
—
cases:1.44%
controls:0.20%
cases:4.72%
controls:0.44%
cases:9.12%
controls:1.22%
22
33
326
3447
12
21
336
3459
6
5
342
3475
—
5
7
343
3468
16
15
323
3363
25
33
249
2681
Pulmonary Disease
29 [38004472]
29 [38004472]
1.4e+00
1.8e+00
2.1e+00
1.0e+50
1.4e+00
2.1e+00
1.7e+00
cases:20.69%
controls:5.80%
cases:15.52%
controls:2.93%
cases:4.60%
controls:0.57%
cases:6.90%
controls:0.00%
cases:3.16%
controls:0.78%
cases:19.17%
controls:2.81%
cases:24.82%
controls:5.75%
72
202
276
3278
54
102
294
3378
16
20
332
3460
24
0
324
3480
11
27
337
3448
65
95
274
3283
68
156
206
2558
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
1.5e+00
1.9e+00
2.6e+00
—
1.9e+00
1.3e+00
1.3e+00
cases:26.15%
controls:7.18%
cases:19.83%
controls:3.62%
cases:3.16%
controls:0.23%
—
—
cases:2.01%
controls:0.32%
cases:12.39%
controls:3.61%
cases:29.93%
controls:10.83%
91
250
257
3230
69
126
279
3354
11
8
337
3472
—
7
11
341
3464
42
122
297
3256
82
294
192
2420
pramipexole; oral
N04BC05 [21604477]
N04BC05 [21604477]
2.4e+00
2.7e+00
—
—
—
2.8e+00
2.4e+00
cases:6.03%
controls:0.57%
cases:5.46%
controls:0.40%
—
—
—
—
—
—
cases:7.37%
controls:0.47%
cases:8.03%
controls:0.77%
21
20
327
3460
19
14
329
3466
—
—
—
25
16
314
3362
22
21
252
2693
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
2742-5 [3034780]
2.4e+00
2.6e+00
—
—
—
3.4e+00
1.9e+00
cases:5.46%
controls:0.55%
cases:4.31%
controls:0.34%
—
—
—
—
—
—
cases:4.42%
controls:0.15%
cases:5.84%
controls:0.92%
19
19
329
3461
15
12
333
3468
—
—
—
15
5
324
3373
16
25
258
2689
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
31374-2 [3007080]
2.3e+00
3.5e+00
1.0e+50
—
—
2.2e+00
2.2e+00
cases:8.33%
controls:0.92%
cases:6.03%
controls:0.20%
cases:2.59%
controls:0.00%
—
—
—
—
cases:2.65%
controls:0.30%
cases:3.65%
controls:0.41%
29
32
319
3448
21
7
327
3473
9
0
339
3480
—
—
9
10
330
3368
10
11
264
2703
vortioxetine; oral
N06AX26 [44819158]
N06AX26 [44819158]
1.2e+00
1.6e+00
2.0e+00
—
2.2e+00
1.9e+00
1.1e+00
cases:5.17%
controls:1.67%
cases:6.03%
controls:1.29%
cases:1.72%
controls:0.23%
—
—
cases:2.30%
controls:0.26%
cases:5.60%
controls:0.92%
cases:8.39%
controls:2.84%
18
58
330
3422
21
45
327
3435
6
8
342
3472
—
8
9
340
3466
19
31
320
3347
23
77
251
2637
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
1.2e+00
1.5e+00
—
—
2.9e+00
2.4e+00
1.9e+00
cases:14.08%
controls:4.74%
cases:6.90%
controls:1.55%
—
—
—
—
cases:2.59%
controls:0.14%
cases:12.09%
controls:1.24%
cases:18.25%
controls:3.10%
49
165
299
3315
24
54
324
3426
—
—
9
5
339
3470
41
42
298
3336
50
84
224
2630
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 [3007844]
5159-9 [3007844]
2.2e+00
3.5e+00
1.0e+50
—
—
2.1e+00
1.9e+00
cases:8.33%
controls:1.03%
cases:6.03%
controls:0.20%
cases:2.59%
controls:0.00%
—
—
—
—
cases:2.65%
controls:0.33%
cases:3.65%
controls:0.55%
29
36
319
3444
21
7
327
3473
9
0
339
3480
—
—
9
11
330
3367
10
15
264
2699
Dysthymia
F34.1 [45586238]
F34.1 [45586238]
2.5e+00
2.7e+00
—
—
—
2.4e+00
2.0e+00
cases:5.17%
controls:0.43%
cases:2.87%
controls:0.20%
—
—
—
—
—
—
cases:2.65%
controls:0.24%
cases:4.01%
controls:0.59%
18
15
330
3465
10
7
338
3473
—
—
—
9
8
330
3370
11
16
263
2698
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
7818-8 [3008230]
2.6e+00
3.1e+00
—
—
—
2.2e+00
1.7e+00
cases:19.54%
controls:1.81%
cases:12.93%
controls:0.69%
—
—
—
—
—
—
cases:4.42%
controls:0.53%
cases:9.12%
controls:1.88%
68
63
280
3417
45
24
303
3456
—
—
—
15
18
324
3360
25
51
249
2663
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
1.3e+00
1.5e+00
2.2e+00
—
1.8e+00
1.2e+00
1.4e+00
cases:27.01%
controls:8.97%
cases:17.53%
controls:4.45%
cases:5.17%
controls:0.60%
—
—
cases:4.02%
controls:0.72%
cases:10.32%
controls:3.43%
cases:32.12%
controls:10.02%
94
312
254
3168
61
155
287
3325
18
21
330
3459
—
14
25
334
3450
35
116
304
3262
88
272
186
2442
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
1.3e+00
1.6e+00
2.4e+00
—
1.8e+00
1.0e+00
1.2e+00
cases:53.16%
controls:23.16%
cases:36.49%
controls:10.80%
cases:13.51%
controls:1.35%
—
—
cases:8.05%
controls:1.44%
cases:24.78%
controls:10.81%
cases:56.93%
controls:28.56%
185
806
163
2674
127
376
221
3104
47
47
301
3433
—
28
50
320
3425
84
365
255
3013
156
775
118
1939
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
7.9e-01
1.1e+00
1.8e+00
2.2e+00
1.2e+00
1.1e+00
1.0e+00
cases:56.03%
controls:36.67%
cases:47.41%
controls:22.53%
cases:16.67%
controls:3.19%
cases:2.59%
controls:0.29%
cases:11.49%
controls:3.65%
cases:45.43%
controls:22.23%
cases:71.53%
controls:48.12%
195
1276
153
2204
165
784
183
2696
58
111
290
3369
9
10
339
3470
40
127
308
3348
154
751
185
2627
196
1306
78
1408
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
1.3e+00
1.5e+00
2.3e+00
—
1.7e+00
1.1e+00
1.3e+00
cases:28.74%
controls:9.89%
cases:19.83%
controls:5.26%
cases:6.03%
controls:0.66%
—
—
cases:4.31%
controls:0.81%
cases:11.80%
controls:4.14%
cases:34.67%
controls:12.60%
100
344
248
3136
69
183
279
3297
21
23
327
3457
—
15
28
333
3447
40
140
299
3238
95
342
179
2372
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
7817-0 [3016888]
2.5e+00
2.9e+00
—
—
—
2.1e+00
1.6e+00
cases:17.82%
controls:1.67%
cases:11.21%
controls:0.66%
—
—
—
—
—
—
cases:3.24%
controls:0.41%
cases:8.03%
controls:1.77%
62
58
286
3422
39
23
309
3457
—
—
—
11
14
328
3364
22
48
252
2666
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
8.0e-01
1.1e+00
1.8e+00
2.2e+00
1.2e+00
1.0e+00
9.9e-01
cases:56.61%
controls:37.04%
cases:47.70%
controls:22.53%
cases:16.67%
controls:3.28%
cases:2.59%
controls:0.29%
cases:11.49%
controls:3.74%
cases:43.95%
controls:22.32%
cases:71.53%
controls:48.27%
197
1289
151
2191
166
784
182
2696
58
114
290
3366
9
10
339
3470
40
130
308
3345
149
754
190
2624
196
1310
78
1404
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
1.7e+00
1.7e+00
—
—
2.5e+00
1.8e+00
1.5e+00
cases:12.93%
controls:2.67%
cases:8.33%
controls:1.67%
—
—
—
—
cases:1.72%
controls:0.14%
cases:7.37%
controls:1.30%
cases:17.15%
controls:4.61%
45
93
303
3387
29
58
319
3422
—
—
6
5
342
3470
25
44
314
3334
47
125
227
2589
Depressive episode, unspecified
F32.9 [45571760]
F32.9 [45571760]
1.2e+00
1.2e+00
2.2e+00
1.0e+50
2.1e+00
1.4e+00
1.1e+00
cases:7.18%
controls:2.24%
cases:4.31%
controls:1.35%
cases:1.72%
controls:0.20%
cases:2.01%
controls:0.00%
cases:2.30%
controls:0.29%
cases:5.31%
controls:1.42%
cases:9.49%
controls:3.54%
25
78
323
3402
15
47
333
3433
6
7
342
3473
7
0
341
3480
8
10
340
3465
18
48
321
3330
26
96
248
2618
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
8.0e-01
1.6e+00
2.5e+00
—
2.5e+00
1.4e+00
1.1e+00
cases:2.59%
controls:1.18%
cases:3.74%
controls:0.78%
cases:2.30%
controls:0.20%
—
—
cases:1.72%
controls:0.14%
cases:3.83%
controls:1.01%
cases:8.03%
controls:2.84%
9
41
339
3439
13
27
335
3453
8
7
340
3473
—
6
5
342
3470
13
34
326
3344
22
77
252
2637
Generalized anxiety disorder
F41.1 [45571764]
F41.1 [45571764]
1.4e+00
1.7e+00
1.8e+00
—
2.7e+00
1.7e+00
1.5e+00
cases:4.02%
controls:1.06%
cases:3.45%
controls:0.63%
cases:1.44%
controls:0.23%
—
—
cases:2.01%
controls:0.14%
cases:5.01%
controls:0.92%
cases:10.58%
controls:2.54%
14
37
334
3443
12
22
336
3458
5
8
343
3472
—
7
5
341
3470
17
31
322
3347
29
69
245
2645
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
9.3e-01
1.7e+00
2.5e+00
—
2.5e+00
1.3e+00
1.0e+00
cases:2.59%
controls:1.03%
cases:4.02%
controls:0.78%
cases:2.30%
controls:0.20%
—
—
cases:1.72%
controls:0.14%
cases:3.83%
controls:1.04%
cases:8.03%
controls:3.10%
9
36
339
3444
14
27
334
3453
8
7
340
3473
—
6
5
342
3470
13
35
326
3343
22
84
252
2630
Internal Medicine
11 [38004456]
11 [38004456]
1.1e+00
1.5e+00
1.5e+00
—
2.0e+00
1.5e+00
1.2e+00
cases:35.06%
controls:14.68%
cases:20.98%
controls:5.46%
cases:4.02%
controls:0.89%
—
—
cases:6.61%
controls:0.95%
cases:19.76%
controls:5.18%
cases:29.20%
controls:10.91%
122
511
226
2969
73
190
275
3290
14
31
334
3449
—
23
33
325
3442
67
175
272
3203
80
296
194
2418
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
1.5e+00
1.7e+00
—
—
2.5e+00
1.7e+00
1.5e+00
cases:13.22%
controls:3.13%
cases:9.48%
controls:1.81%
—
—
—
—
cases:1.72%
controls:0.14%
cases:7.08%
controls:1.42%
cases:17.52%
controls:4.64%
46
109
302
3371
33
63
315
3417
—
—
6
5
342
3470
24
48
315
3330
48
126
226
2588
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
1.8e+00
1.9e+00
9.0e-01
1.7e+00
1.2e+00
1.5e+00
1.8e+00
cases:99.14%
controls:95.14%
cases:96.84%
controls:82.67%
cases:61.78%
controls:39.57%
cases:9.20%
controls:1.90%
cases:67.24%
controls:38.68%
cases:95.87%
controls:83.27%
cases:99.27%
controls:95.54%
345
3311
3
169
337
2877
11
603
215
1377
133
2103
32
66
316
3414
234
1344
114
2131
325
2813
14
565
272
2593
2
121
bupropion; oral
N06AX12 [21604741]
N06AX12 [21604741]
1.7e+00
1.9e+00
1.8e+00
—
1.3e+00
1.8e+00
1.6e+00
cases:11.21%
controls:2.18%
cases:8.91%
controls:1.41%
cases:2.59%
controls:0.43%
—
—
cases:2.01%
controls:0.55%
cases:7.37%
controls:1.30%
cases:12.41%
controls:2.69%
39
76
309
3404
31
49
317
3431
9
15
339
3465
—
7
19
341
3456
25
44
314
3334
34
73
240
2641
Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]
IDY03 [2001304164]
1.9e+00
2.2e+00
—
1.0e+50
—
2.9e+00
1.8e+00
cases:4.60%
controls:0.69%
cases:3.74%
controls:0.43%
—
—
cases:2.30%
controls:0.00%
—
—
cases:8.26%
controls:0.47%
cases:9.12%
controls:1.58%
16
24
332
3456
13
15
335
3465
—
8
0
340
3480
—
28
16
311
3362
25
43
249
2671
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
AA1BG [2001300112]
1.5e+00
3.2e+00
—
—
—
2.7e+00
1.5e+00
cases:4.89%
controls:1.12%
cases:5.75%
controls:0.26%
—
—
—
—
—
—
cases:3.54%
controls:0.24%
cases:4.38%
controls:1.03%
17
39
331
3441
20
9
328
3471
—
—
—
12
8
327
3370
12
28
262
2686
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
22246-3 [3017918]
2.2e+00
3.2e+00
—
—
—
1.9e+00
1.6e+00
cases:7.76%
controls:0.92%
cases:5.75%
controls:0.26%
—
—
—
—
—
—
cases:2.65%
controls:0.41%
cases:3.65%
controls:0.74%
27
32
321
3448
20
9
328
3471
—
—
—
9
14
330
3364
10
20
264
2694
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
7.8e-01
1.5e+00
2.3e+00
—
2.5e+00
1.4e+00
1.1e+00
cases:2.59%
controls:1.21%
cases:3.74%
controls:0.83%
cases:2.30%
controls:0.23%
—
—
cases:1.72%
controls:0.14%
cases:4.13%
controls:1.01%
cases:8.03%
controls:2.95%
9
42
339
3438
13
29
335
3451
8
8
340
3472
—
6
5
342
3470
14
34
325
3344
22
80
252
2634
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
30342-0 [3015171]
1.9e+00
3.2e+00
—
—
—
2.2e+00
1.5e+00
cases:8.33%
controls:1.32%
cases:7.18%
controls:0.32%
—
—
—
—
—
—
cases:4.13%
controls:0.47%
cases:4.74%
controls:1.14%
29
46
319
3434
25
11
323
3469
—
—
—
14
16
325
3362
13
31
261
2683
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
1.3e+00
1.4e+00
2.0e+00
—
1.7e+00
1.1e+00
1.3e+00
cases:31.32%
controls:11.18%
cases:21.26%
controls:6.03%
cases:3.74%
controls:0.55%
—
—
cases:3.74%
controls:0.72%
cases:17.70%
controls:6.39%
cases:41.61%
controls:16.80%
109
389
239
3091
74
210
274
3270
13
19
335
3461
—
13
25
335
3450
60
216
279
3162
114
456
160
2258
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
5.5e-01
9.6e-01
1.8e+00
2.5e+00
1.2e+00
9.8e-01
8.0e-01
cases:43.68%
controls:30.86%
cases:40.80%
controls:20.80%
cases:16.67%
controls:3.28%
cases:1.72%
controls:0.14%
cases:10.63%
controls:3.57%
cases:41.30%
controls:20.93%
cases:62.04%
controls:42.37%
152
1074
196
2406
142
724
206
2756
58
114
290
3366
6
5
342
3475
37
124
311
3351
140
707
199
2671
170
1150
104
1564
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
1.0e+00
1.5e+00
2.2e+00
—
1.8e+00
1.0e+00
1.1e+00
cases:31.03%
controls:14.02%
cases:29.02%
controls:8.28%
cases:11.78%
controls:1.41%
—
—
cases:8.33%
controls:1.55%
cases:19.47%
controls:8.20%
cases:39.05%
controls:16.95%
108
488
240
2992
101
288
247
3192
41
49
307
3431
—
29
54
319
3421
66
277
273
3101
107
460
167
2254
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
1.0e+00
1.5e+00
2.2e+00
—
1.8e+00
1.0e+00
1.2e+00
cases:31.03%
controls:14.02%
cases:29.02%
controls:8.30%
cases:11.78%
controls:1.44%
—
—
cases:8.33%
controls:1.55%
cases:19.47%
controls:8.20%
cases:39.05%
controls:16.84%
108
488
240
2992
101
289
247
3191
41
50
307
3430
—
29
54
319
3421
66
277
273
3101
107
457
167
2257
Outpatient Visit
OP [9202]
OP [9202]
5.7e-01
6.2e-01
9.3e-01
4.6e+00
1.2e+00
7.3e-01
4.5e-01
cases:85.63%
controls:77.10%
cases:68.39%
controls:53.71%
cases:24.43%
controls:11.29%
cases:39.94%
controls:0.69%
cases:29.02%
controls:10.79%
cases:68.44%
controls:51.12%
cases:83.94%
controls:76.97%
298
2683
50
797
238
1869
110
1611
85
393
263
3087
139
24
209
3456
101
375
247
3100
232
1727
107
1651
230
2089
44
625
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
1.0e+00
1.5e+00
2.2e+00
—
1.8e+00
9.8e-01
1.1e+00
cases:31.32%
controls:14.02%
cases:29.02%
controls:8.30%
cases:11.78%
controls:1.47%
—
—
cases:8.33%
controls:1.53%
cases:19.47%
controls:8.32%
cases:39.05%
controls:16.91%
109
488
239
2992
101
289
247
3191
41
51
307
3429
—
29
53
319
3422
66
281
273
3097
107
459
167
2255
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
1.5e+00
2.8e+00
—
—
—
2.1e+00
2.2e+00
cases:2.87%
controls:0.63%
cases:5.46%
controls:0.34%
—
—
—
—
—
—
cases:4.13%
controls:0.53%
cases:8.03%
controls:0.99%
10
22
338
3458
19
12
329
3468
—
—
—
14
18
325
3360
22
27
252
2687
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
6.7e-01
1.1e+00
1.7e+00
2.2e+00
1.5e+00
7.3e-01
7.0e-01
cases:58.05%
controls:41.35%
cases:47.99%
controls:23.45%
cases:18.10%
controls:3.85%
cases:2.01%
controls:0.23%
cases:15.23%
controls:3.88%
cases:38.35%
controls:23.12%
cases:67.52%
controls:50.74%
202
1439
146
2041
167
816
181
2664
63
134
285
3346
7
8
341
3472
53
135
295
3340
130
781
209
2597
185
1377
89
1337
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
9.9e-01
1.5e+00
2.3e+00
—
1.8e+00
9.4e-01
1.1e+00
cases:31.03%
controls:14.34%
cases:28.45%
controls:8.45%
cases:12.36%
controls:1.41%
—
—
cases:8.62%
controls:1.55%
cases:19.17%
controls:8.50%
cases:39.05%
controls:17.58%
108
499
240
2981
99
294
249
3186
43
49
305
3431
—
30
54
318
3421
65
287
274
3091
107
477
167
2237
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
1.1e+00
1.5e+00
2.2e+00
—
1.7e+00
9.3e-01
1.1e+00
cases:33.05%
controls:14.57%
cases:29.02%
controls:8.51%
cases:12.07%
controls:1.47%
—
—
cases:8.33%
controls:1.58%
cases:19.47%
controls:8.70%
cases:40.15%
controls:17.94%
115
507
233
2973
101
296
247
3184
42
51
306
3429
—
29
55
319
3420
66
294
273
3084
110
487
164
2227
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
K58.0 [45596336]
1.7e+00
2.1e+00
—
—
—
3.0e+00
1.7e+00
cases:4.60%
controls:0.86%
cases:2.30%
controls:0.29%
—
—
—
—
—
—
cases:2.95%
controls:0.15%
cases:5.11%
controls:0.96%
16
30
332
3450
8
10
340
3470
—
—
—
10
5
329
3373
14
26
260
2688
propranolol; oral, parenteral
C07AA05 [21601670]
C07AA05 [21601670]
1.2e+00
1.3e+00
1.5e+00
—
1.7e+00
1.5e+00
1.3e+00
cases:18.39%
controls:6.21%
cases:10.63%
controls:3.02%
cases:2.87%
controls:0.66%
—
—
cases:3.16%
controls:0.60%
cases:11.50%
controls:2.93%
cases:22.26%
controls:7.07%
64
216
284
3264
37
105
311
3375
10
23
338
3457
—
11
21
337
3454
39
99
300
3279
61
192
213
2522
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
7853-5 [3015635]
2.0e+00
3.2e+00
—
—
—
1.8e+00
1.6e+00
cases:6.90%
controls:0.98%
cases:5.17%
controls:0.23%
—
—
—
—
—
—
cases:2.36%
controls:0.41%
cases:3.28%
controls:0.70%
24
34
324
3446
18
8
330
3472
—
—
—
8
14
331
3364
9
19
265
2695
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
Z00.4 [45605094]
1.8e+00
2.3e+00
—
—
—
2.6e+00
1.7e+00
cases:11.78%
controls:2.10%
cases:6.32%
controls:0.66%
—
—
—
—
—
—
cases:9.44%
controls:0.74%
cases:11.68%
controls:2.36%
41
73
307
3407
22
23
326
3457
—
—
—
32
25
307
3353
32
64
242
2650
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
1.1e+00
1.5e+00
2.1e+00
—
1.7e+00
9.7e-01
1.2e+00
cases:34.20%
controls:15.03%
cases:29.89%
controls:8.76%
cases:11.78%
controls:1.67%
—
—
cases:8.33%
controls:1.70%
cases:20.65%
controls:8.94%
cases:41.97%
controls:18.39%
119
523
229
2957
104
305
244
3175
41
58
307
3422
—
29
59
319
3416
70
302
269
3076
115
499
159
2215
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
OMOP4821991 [45756751]
1.8e+00
2.1e+00
—
—
—
2.3e+00
2.2e+00
cases:4.31%
controls:0.78%
cases:2.59%
controls:0.32%
—
—
—
—
—
—
cases:2.65%
controls:0.27%
cases:6.20%
controls:0.70%
15
27
333
3453
9
11
339
3469
—
—
—
9
9
330
3369
17
19
257
2695
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
1.5e+00
2.1e+00
2.5e+00
—
—
1.6e+00
8.7e-01
cases:10.92%
controls:2.79%
cases:7.47%
controls:1.01%
cases:2.01%
controls:0.17%
—
—
—
—
cases:5.01%
controls:1.10%
cases:8.03%
controls:3.54%
38
97
310
3383
26
35
322
3445
7
6
341
3474
—
—
17
37
322
3341
22
96
252
2618
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
1.1e+00
1.5e+00
2.1e+00
—
1.7e+00
9.7e-01
1.2e+00
cases:34.20%
controls:15.06%
cases:29.89%
controls:8.82%
cases:11.78%
controls:1.67%
—
—
cases:8.33%
controls:1.70%
cases:20.65%
controls:8.94%
cases:41.97%
controls:18.35%
119
524
229
2956
104
307
244
3173
41
58
307
3422
—
29
59
319
3416
70
302
269
3076
115
498
159
2216
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
2.0e+00
2.7e+00
1.0e+50
1.0e+50
—
2.5e+00
1.2e+00
cases:8.91%
controls:1.35%
cases:8.05%
controls:0.60%
cases:2.30%
controls:0.00%
cases:1.44%
controls:0.00%
—
—
cases:4.72%
controls:0.38%
cases:7.66%
controls:2.36%
31
47
317
3433
28
21
320
3459
8
0
340
3480
5
0
343
3480
—
16
13
323
3365
21
64
253
2650
Emergency Medicine
93 [38004510]
93 [38004510]
6.5e-01
8.5e-01
1.2e+00
2.9e+00
1.4e+00
6.4e-01
6.5e-01
cases:30.17%
controls:18.33%
cases:20.40%
controls:9.89%
cases:4.60%
controls:1.41%
cases:2.59%
controls:0.14%
cases:5.17%
controls:1.27%
cases:15.93%
controls:9.06%
cases:39.05%
controls:25.09%
105
638
243
2842
71
344
277
3136
16
49
332
3431
9
5
339
3475
18
44
330
3431
54
306
285
3072
107
681
167
2033
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
1.6e+00
1.6e+00
—
—
2.3e+00
1.7e+00
1.2e+00
cases:11.49%
controls:2.56%
cases:5.75%
controls:1.24%
—
—
—
—
cases:2.30%
controls:0.23%
cases:6.19%
controls:1.18%
cases:9.49%
controls:3.21%
40
89
308
3391
20
43
328
3437
—
—
8
8
340
3467
21
40
318
3338
26
87
248
2627
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
1.1e+00
1.5e+00
2.1e+00
—
1.6e+00
9.2e-01
1.1e+00
cases:35.92%
controls:15.49%
cases:30.17%
controls:9.02%
cases:11.78%
controls:1.67%
—
—
cases:8.33%
controls:1.73%
cases:20.35%
controls:9.21%
cases:42.34%
controls:19.09%
125
539
223
2941
105
314
243
3166
41
58
307
3422
—
29
60
319
3415
69
311
270
3067
116
518
158
2196
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
1.4e+00
1.6e+00
1.7e+00
—
1.5e+00
1.2e+00
1.1e+00
cases:40.80%
controls:14.94%
cases:33.05%
controls:9.40%
cases:6.03%
controls:1.18%
—
—
cases:5.46%
controls:1.29%
cases:27.14%
controls:10.51%
cases:50.73%
controls:25.53%
142
520
206
2960
115
327
233
3153
21
41
327
3439
—
19
45
329
3430
92
355
247
3023
139
693
135
2021
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
1.1e+00
1.5e+00
2.1e+00
—
1.6e+00
9.4e-01
1.1e+00
cases:35.06%
controls:15.60%
cases:30.46%
controls:9.02%
cases:12.36%
controls:1.70%
—
—
cases:8.33%
controls:1.76%
cases:20.65%
controls:9.24%
cases:42.70%
controls:19.68%
122
543
226
2937
106
314
242
3166
43
59
305
3421
—
29
61
319
3414
70
312
269
3066
117
534
157
2180
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.3e+00
2.2e+00
—
—
—
2.5e+00
2.3e+00
cases:5.46%
controls:1.52%
cases:3.16%
controls:0.34%
—
—
—
—
—
—
cases:7.08%
controls:0.62%
cases:14.23%
controls:1.69%
19
53
329
3427
11
12
337
3468
—
—
—
24
21
315
3357
39
46
235
2668
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
1.4e+00
1.1e+00
—
—
2.9e+00
1.5e+00
1.4e+00
cases:8.62%
controls:2.30%
cases:4.02%
controls:1.32%
—
—
—
—
cases:3.16%
controls:0.17%
cases:6.19%
controls:1.51%
cases:12.41%
controls:3.39%
30
80
318
3400
14
46
334
3434
—
—
11
6
337
3469
21
51
318
3327
34
92
240
2622
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
6.4e-01
1.0e+00
1.5e+00
2.3e+00
1.0e+00
9.2e-01
8.0e-01
cases:59.20%
controls:43.42%
cases:53.16%
controls:29.02%
cases:19.25%
controls:4.86%
cases:2.30%
controls:0.23%
cases:13.51%
controls:5.24%
cases:50.15%
controls:28.63%
cases:75.55%
controls:58.11%
206
1511
142
1969
185
1010
163
2470
67
169
281
3311
8
8
340
3472
47
182
301
3293
170
967
169
2411
207
1577
67
1137
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
1845-7 [3023183]
3.2e+00
—
—
—
—
2.7e+00
2.5e+00
cases:6.32%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.06%
controls:0.15%
cases:2.92%
controls:0.26%
22
10
326
3470
—
—
—
—
7
5
332
3373
8
7
266
2707
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
1.3e+00
1.5e+00
1.3e+00
—
2.1e+00
1.9e+00
1.5e+00
cases:12.93%
controls:3.91%
cases:8.05%
controls:1.93%
cases:2.30%
controls:0.66%
—
—
cases:4.02%
controls:0.52%
cases:11.50%
controls:1.95%
cases:14.60%
controls:3.72%
45
136
303
3344
28
67
320
3413
8
23
340
3457
—
14
18
334
3457
39
66
300
3312
40
101
234
2613
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
1.2e+00
1.4e+00
2.0e+00
—
1.5e+00
9.2e-01
1.2e+00
cases:23.28%
controls:8.71%
cases:20.40%
controls:5.95%
cases:7.76%
controls:1.09%
—
—
cases:5.17%
controls:1.15%
cases:12.98%
controls:5.60%
cases:29.20%
controls:11.46%
81
303
267
3177
71
207
277
3273
27
38
321
3442
—
18
40
330
3435
44
189
295
3189
80
311
194
2403
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
49178-7 [3048929]
1.8e+00
2.9e+00
1.0e+50
—
—
1.9e+00
1.5e+00
cases:10.06%
controls:1.75%
cases:6.90%
controls:0.40%
cases:2.87%
controls:0.00%
—
—
—
—
cases:3.54%
controls:0.53%
cases:5.47%
controls:1.25%
35
61
313
3419
24
14
324
3466
10
0
338
3480
—
—
12
18
327
3360
15
34
259
2680
Weakness/tiredness general
A04 [2002000145]
A04 [2002000145]
1.6e+00
2.5e+00
—
—
—
2.1e+00
1.9e+00
cases:10.92%
controls:2.33%
cases:9.48%
controls:0.83%
—
—
—
—
—
—
cases:5.90%
controls:0.80%
cases:17.88%
controls:3.06%
38
81
310
3399
33
29
315
3451
—
—
—
20
27
319
3351
49
83
225
2631
epinephrine; parenteral
C01CA24 [21600303]
C01CA24 [21600303]
2.1e+00
1.8e+00
—
—
—
2.1e+00
2.1e+00
cases:10.92%
controls:1.44%
cases:3.45%
controls:0.60%
—
—
—
—
—
—
cases:3.24%
controls:0.41%
cases:9.85%
controls:1.33%
38
50
310
3430
12
21
336
3459
—
—
—
11
14
328
3364
27
36
247
2678
epinephrine
S01EA01 [21603673]
S01EA01 [21603673]
2.1e+00
1.8e+00
—
—
—
2.1e+00
2.1e+00
cases:10.92%
controls:1.44%
cases:3.45%
controls:0.60%
—
—
—
—
—
—
cases:3.24%
controls:0.41%
cases:9.85%
controls:1.33%
38
50
310
3430
12
21
336
3459
—
—
—
11
14
328
3364
27
36
247
2678
Neuropsychological investigation
XA800 [2001300412]
XA800 [2001300412]
2.9e+00
1.7e+00
—
—
—
2.8e+00
2.3e+00
cases:5.46%
controls:0.32%
cases:1.44%
controls:0.26%
—
—
—
—
—
—
cases:3.83%
controls:0.24%
cases:3.28%
controls:0.33%
19
11
329
3469
5
9
343
3471
—
—
—
13
8
326
3370
9
9
265
2705
Moderate depressive episode with somatic syndrome
F32.11 [2000501981]
F32.11 [2000501981]
2.9e+00
2.7e+00
—
—
—
—
2.5e+00
cases:3.45%
controls:0.20%
cases:2.01%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.55%
controls:0.22%
12
7
336
3473
7
5
341
3475
—
—
—
—
7
6
267
2708
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
1.5e+00
1.5e+00
2.7e+00
—
—
1.4e+00
8.7e-01
cases:10.92%
controls:2.56%
cases:8.33%
controls:1.95%
cases:2.01%
controls:0.14%
—
—
—
—
cases:7.96%
controls:2.13%
cases:15.69%
controls:7.22%
38
89
310
3391
29
68
319
3412
7
5
341
3475
—
—
27
72
312
3306
43
196
231
2518
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
Z50.9 [45595525]
1.8e+00
—
—
—
—
3.1e+00
3.0e+00
cases:2.87%
controls:0.49%
—
—
—
—
—
—
—
—
cases:3.24%
controls:0.15%
cases:5.84%
controls:0.29%
10
17
338
3463
—
—
—
—
11
5
328
3373
16
8
258
2706
Observation for suspected nervous system disorder
Z03.3 [45609903]
Z03.3 [45609903]
2.4e+00
—
1.0e+50
—
—
3.4e+00
2.1e+00
cases:5.17%
controls:0.49%
—
—
cases:1.72%
controls:0.00%
—
—
—
—
cases:4.13%
controls:0.15%
cases:3.65%
controls:0.44%
18
17
330
3463
—
6
0
342
3480
—
—
14
5
325
3373
10
12
264
2702
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2589-0 [3012110]
2.3e+00
3.0e+00
—
—
—
—
2.6e+00
cases:3.45%
controls:0.34%
cases:3.45%
controls:0.17%
—
—
—
—
—
—
—
—
cases:5.84%
controls:0.48%
12
12
336
3468
12
6
336
3474
—
—
—
—
16
13
258
2701
Headache
R51.80 [2000503603]
R51.80 [2000503603]
1.6e+00
2.6e+00
—
—
—
1.8e+00
1.9e+00
cases:12.64%
controls:2.82%
cases:9.48%
controls:0.78%
—
—
—
—
—
—
cases:5.90%
controls:1.04%
cases:17.15%
controls:2.95%
44
98
304
3382
33
27
315
3453
—
—
—
20
35
319
3343
47
80
227
2634
montelukast; oral
R03DC03 [21603356]
R03DC03 [21603356]
1.2e+00
1.5e+00
1.1e+00
—
2.0e+00
1.6e+00
1.6e+00
cases:10.92%
controls:3.56%
cases:7.47%
controls:1.84%
cases:1.72%
controls:0.57%
—
—
cases:2.59%
controls:0.35%
cases:10.03%
controls:2.19%
cases:14.60%
controls:3.39%
38
124
310
3356
26
64
322
3416
6
20
342
3460
—
9
12
339
3463
34
74
305
3304
40
92
234
2622
Cardiology
6 [38004451]
6 [38004451]
1.0e+00
1.5e+00
1.6e+00
1.0e+50
2.3e+00
2.0e+00
1.0e+00
cases:13.22%
controls:5.23%
cases:9.20%
controls:2.21%
cases:1.44%
controls:0.29%
cases:1.44%
controls:0.00%
cases:2.59%
controls:0.26%
cases:11.80%
controls:1.84%
cases:15.33%
controls:6.19%
46
182
302
3298
32
77
316
3403
5
10
343
3470
5
0
343
3480
9
9
339
3466
40
62
299
3316
42
168
232
2546
Observation for other suspected diseases and conditions
Z03.80 [2000503756]
Z03.80 [2000503756]
2.1e+00
2.9e+00
—
—
—
—
2.7e+00
cases:3.74%
controls:0.46%
cases:2.59%
controls:0.14%
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.22%
13
16
335
3464
9
5
339
3475
—
—
—
—
9
6
265
2708
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
1.3e+00
2.6e+00
2.3e+00
—
—
2.3e+00
1.7e+00
cases:9.48%
controls:2.84%
cases:8.91%
controls:0.75%
cases:1.44%
controls:0.14%
—
—
—
—
cases:8.26%
controls:0.92%
cases:13.50%
controls:2.91%
33
99
315
3381
31
26
317
3454
5
5
343
3475
—
—
28
31
311
3347
37
79
237
2635
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
29953-7 [3037522]
1.8e+00
2.7e+00
—
—
—
1.9e+00
1.3e+00
cases:19.54%
controls:3.91%
cases:18.39%
controls:1.47%
—
—
—
—
—
—
cases:7.37%
controls:1.12%
cases:15.33%
controls:4.72%
68
136
280
3344
64
51
284
3429
—
—
—
25
38
314
3340
42
128
232
2586
Other specified intervertebral disc degeneration
M51.3 [45591865]
M51.3 [45591865]
1.4e+00
2.1e+00
—
—
—
2.4e+00
1.8e+00
cases:3.45%
controls:0.86%
cases:2.30%
controls:0.29%
—
—
—
—
—
—
cases:2.95%
controls:0.27%
cases:5.11%
controls:0.88%
12
30
336
3450
8
10
340
3470
—
—
—
10
9
329
3369
14
24
260
2690
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
1.1e+00
1.8e+00
2.7e+00
—
1.5e+00
1.1e+00
9.7e-01
cases:18.68%
controls:7.36%
cases:11.78%
controls:2.10%
cases:3.74%
controls:0.26%
—
—
cases:1.72%
controls:0.37%
cases:6.49%
controls:2.16%
cases:17.15%
controls:7.30%
65
256
283
3224
41
73
307
3407
13
9
335
3471
—
6
13
342
3462
22
73
317
3305
47
198
227
2516
Mixed anxiety and depressive disorder
F41.2 [45566845]
F41.2 [45566845]
1.5e+00
1.4e+00
2.5e+00
1.0e+50
—
1.5e+00
7.8e-01
cases:8.91%
controls:2.16%
cases:5.17%
controls:1.35%
cases:2.30%
controls:0.20%
cases:1.44%
controls:0.00%
—
—
cases:4.42%
controls:0.98%
cases:9.12%
controls:4.38%
31
75
317
3405
18
47
330
3433
8
7
340
3473
5
0
343
3480
—
15
33
324
3345
25
119
249
2595
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
A04AA01 [21600493]
1.7e+00
1.8e+00
—
—
—
2.2e+00
2.0e+00
cases:3.45%
controls:0.63%
cases:2.01%
controls:0.34%
—
—
—
—
—
—
cases:2.06%
controls:0.24%
cases:4.74%
controls:0.70%
12
22
336
3458
7
12
341
3468
—
—
—
7
8
332
3370
13
19
261
2695
Occupational therapy
R4120 [2001310234]
R4120 [2001310234]
1.9e+00
—
—
—
—
3.0e+00
2.6e+00
cases:3.45%
controls:0.52%
—
—
—
—
—
—
—
—
cases:5.31%
controls:0.27%
cases:6.93%
controls:0.55%
12
18
336
3462
—
—
—
—
18
9
321
3369
19
15
255
2699
Predominantly allergic asthma
J45.0 [45557624]
J45.0 [45557624]
1.6e+00
1.6e+00
2.1e+00
1.0e+50
—
2.5e+00
1.8e+00
cases:6.32%
controls:1.41%
cases:4.02%
controls:0.83%
cases:1.44%
controls:0.17%
cases:3.16%
controls:0.00%
—
—
cases:5.90%
controls:0.50%
cases:6.93%
controls:1.25%
22
49
326
3431
14
29
334
3451
5
6
343
3474
11
0
337
3480
—
20
17
319
3361
19
34
255
2680
venlafaxine; oral
N06AX16 [21604745]
N06AX16 [21604745]
1.5e+00
1.5e+00
1.0e+00
—
1.6e+00
1.5e+00
1.3e+00
cases:14.37%
controls:3.51%
cases:8.62%
controls:2.13%
cases:1.72%
controls:0.63%
—
—
cases:2.87%
controls:0.58%
cases:8.85%
controls:2.10%
cases:11.31%
controls:3.39%
50
122
298
3358
30
74
318
3406
6
22
342
3458
—
10
20
338
3455
30
71
309
3307
31
92
243
2622
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
14928-6 [3026989]
1.6e+00
2.2e+00
—
—
—
1.8e+00
1.8e+00
cases:9.77%
controls:2.18%
cases:7.76%
controls:0.92%
—
—
—
—
—
—
cases:5.60%
controls:0.98%
cases:13.50%
controls:2.43%
34
76
314
3404
27
32
321
3448
—
—
—
19
33
320
3345
37
66
237
2648
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
9.2e-01
1.3e+00
1.8e+00
—
1.4e+00
8.6e-01
1.2e+00
cases:34.77%
controls:17.50%
cases:29.89%
controls:10.57%
cases:12.64%
controls:2.33%
—
—
cases:8.91%
controls:2.42%
cases:21.53%
controls:10.39%
cases:45.99%
controls:20.97%
121
609
227
2871
104
368
244
3112
44
81
304
3399
—
31
84
317
3391
73
351
266
3027
126
569
148
2145
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
1.6e+00
2.1e+00
—
—
—
2.0e+00
1.7e+00
cases:6.61%
controls:1.41%
cases:5.17%
controls:0.69%
—
—
—
—
—
—
cases:4.42%
controls:0.62%
cases:6.93%
controls:1.36%
23
49
325
3431
18
24
330
3456
—
—
—
15
21
324
3357
19
37
255
2677
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
N05BA01 [21604566]
1.1e+00
1.3e+00
—
—
2.1e+00
1.5e+00
1.5e+00
cases:8.05%
controls:2.82%
cases:4.31%
controls:1.26%
—
—
—
—
cases:2.01%
controls:0.26%
cases:4.42%
controls:1.07%
cases:8.39%
controls:2.10%
28
98
320
3382
15
44
333
3436
—
—
7
9
341
3466
15
36
324
3342
23
57
251
2657
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
4498-2 [3017766]
1.8e+00
2.9e+00
—
—
—
2.7e+00
1.3e+00
cases:4.02%
controls:0.69%
cases:4.89%
controls:0.29%
—
—
—
—
—
—
cases:2.06%
controls:0.15%
cases:3.28%
controls:0.88%
14
24
334
3456
17
10
331
3470
—
—
—
7
5
332
3373
9
24
265
2690
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
1.2e+00
1.7e+00
2.0e+00
—
1.2e+00
1.4e+00
1.0e+00
cases:19.25%
controls:6.95%
cases:13.51%
controls:2.64%
cases:2.59%
controls:0.37%
—
—
cases:2.01%
controls:0.60%
cases:10.03%
controls:2.63%
cases:19.71%
controls:8.00%
67
242
281
3238
47
92
301
3388
9
13
339
3467
—
7
21
341
3454
34
89
305
3289
54
217
220
2497
Corticotropin [Mass/volume] in Plasma
2141-0 [3035637]
2141-0 [3035637]
2.3e+00
2.4e+00
—
—
—
—
2.5e+00
cases:3.74%
controls:0.37%
cases:2.59%
controls:0.23%
—
—
—
—
—
—
—
—
cases:4.01%
controls:0.33%
13
13
335
3467
9
8
339
3472
—
—
—
—
11
9
263
2705
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
1.1e+00
1.2e+00
1.6e+00
—
1.2e+00
1.1e+00
1.0e+00
cases:45.40%
controls:22.33%
cases:33.33%
controls:12.82%
cases:11.21%
controls:2.53%
—
—
cases:7.47%
controls:2.27%
cases:30.09%
controls:12.52%
cases:52.55%
controls:28.11%
158
777
190
2703
116
446
232
3034
39
88
309
3392
—
26
79
322
3396
102
423
237
2955
144
763
130
1951
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
1.7e+00
2.2e+00
—
—
—
1.9e+00
1.5e+00
cases:6.90%
controls:1.35%
cases:4.89%
controls:0.57%
—
—
—
—
—
—
cases:4.42%
controls:0.71%
cases:6.57%
controls:1.55%
24
47
324
3433
17
20
331
3460
—
—
—
15
24
324
3354
18
42
256
2672
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
1.2e+00
1.5e+00
1.6e+00
—
2.8e+00
1.7e+00
7.8e-01
cases:8.05%
controls:2.47%
cases:5.75%
controls:1.35%
cases:1.44%
controls:0.29%
—
—
cases:3.16%
controls:0.20%
cases:6.19%
controls:1.18%
cases:6.20%
controls:2.95%
28
86
320
3394
20
47
328
3433
5
10
343
3470
—
11
7
337
3468
21
40
318
3338
17
80
257
2634
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
3.8e-01
5.6e-01
1.1e+00
4.0e+00
9.1e-01
6.4e-01
5.8e-01
cases:86.49%
controls:81.35%
cases:83.91%
controls:74.91%
cases:58.05%
controls:32.27%
cases:54.31%
controls:2.16%
cases:56.32%
controls:34.24%
cases:86.14%
controls:76.61%
cases:93.43%
controls:88.80%
301
2831
47
649
292
2607
56
873
202
1123
146
2357
189
75
159
3405
196
1190
152
2285
292
2588
47
790
256
2410
18
304
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
8.4e-01
1.1e+00
1.8e+00
—
1.5e+00
8.5e-01
1.1e+00
cases:26.72%
controls:13.65%
cases:24.71%
controls:10.11%
cases:10.63%
controls:1.93%
—
—
cases:8.62%
controls:2.10%
cases:20.94%
controls:10.15%
cases:39.05%
controls:17.35%
93
475
255
3005
86
352
262
3128
37
67
311
3413
—
30
73
318
3402
71
343
268
3035
107
471
167
2243
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
4485-9 [3000620]
1.7e+00
2.8e+00
—
—
—
2.7e+00
1.3e+00
cases:4.02%
controls:0.75%
cases:4.89%
controls:0.32%
—
—
—
—
—
—
cases:2.06%
controls:0.15%
cases:3.28%
controls:0.88%
14
26
334
3454
17
11
331
3469
—
—
—
7
5
332
3373
9
24
265
2690
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
N02AE01 [21604287]
1.5e+00
1.8e+00
—
—
—
2.0e+00
1.8e+00
cases:4.60%
controls:1.06%
cases:2.30%
controls:0.37%
—
—
—
—
—
—
cases:3.24%
controls:0.44%
cases:6.93%
controls:1.22%
16
37
332
3443
8
13
340
3467
—
—
—
11
15
328
3363
19
33
255
2681
Pain general/multiple sites
A01 [2002000142]
A01 [2002000142]
1.8e+00
1.9e+00
—
—
—
2.0e+00
1.5e+00
cases:4.31%
controls:0.75%
cases:2.01%
controls:0.32%
—
—
—
—
—
—
cases:2.65%
controls:0.38%
cases:6.93%
controls:1.62%
15
26
333
3454
7
11
341
3469
—
—
—
9
13
330
3365
19
44
255
2670
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-3.2e-01
3.4e-03
8.3e-01
—
—
3.4e+00
3.7e+00
cases:23.85%
controls:30.09%
cases:9.20%
controls:9.17%
cases:2.01%
controls:0.89%
—
—
—
—
cases:9.14%
controls:0.33%
cases:18.98%
controls:0.59%
83
1047
265
2433
32
319
316
3161
7
31
341
3449
—
—
31
11
308
3367
52
16
222
2698
nortriptyline; oral, parenteral
N06AA10 [21604697]
N06AA10 [21604697]
1.8e+00
1.5e+00
—
—
—
2.1e+00
1.7e+00
cases:6.90%
controls:1.26%
cases:3.16%
controls:0.72%
—
—
—
—
—
—
cases:2.95%
controls:0.36%
cases:6.57%
controls:1.33%
24
44
324
3436
11
25
337
3455
—
—
—
10
12
329
3366
18
36
256
2678
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
1.1e+00
1.3e+00
2.0e+00
—
1.7e+00
1.2e+00
1.3e+00
cases:13.79%
controls:5.00%
cases:6.61%
controls:1.84%
cases:1.72%
controls:0.23%
—
—
cases:1.44%
controls:0.26%
cases:4.42%
controls:1.33%
cases:11.31%
controls:3.35%
48
174
300
3306
23
64
325
3416
6
8
342
3472
—
5
9
343
3466
15
45
324
3333
31
91
243
2623
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
9.2e-01
1.3e+00
2.0e+00
—
1.8e+00
6.7e-01
9.5e-01
cases:15.80%
controls:6.98%
cases:11.78%
controls:3.36%
cases:4.02%
controls:0.57%
—
—
cases:2.87%
controls:0.49%
cases:6.49%
controls:3.43%
cases:18.98%
controls:8.33%
55
243
293
3237
41
117
307
3363
14
20
334
3460
—
10
17
338
3458
22
116
317
3262
52
226
222
2488
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
1.0e+00
1.3e+00
—
—
2.3e+00
1.3e+00
1.0e+00
cases:17.82%
controls:7.33%
cases:6.90%
controls:1.93%
—
—
—
—
cases:1.72%
controls:0.17%
cases:7.08%
controls:2.13%
cases:17.15%
controls:6.85%
62
255
286
3225
24
67
324
3413
—
—
6
6
342
3469
24
72
315
3306
47
186
227
2528
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
1.0e+00
1.3e+00
1.9e+00
—
1.4e+00
6.7e-01
5.5e-01
cases:35.63%
controls:16.84%
cases:24.71%
controls:7.84%
cases:4.31%
controls:0.66%
—
—
cases:2.87%
controls:0.72%
cases:12.98%
controls:7.08%
cases:34.31%
controls:23.14%
124
586
224
2894
86
273
262
3207
15
23
333
3457
—
10
25
338
3450
44
239
295
3139
94
628
180
2086
amitriptyline; oral, parenteral
N06AA09 [21604696]
N06AA09 [21604696]
1.4e+00
1.6e+00
—
—
1.6e+00
1.2e+00
1.1e+00
cases:18.68%
controls:5.32%
cases:10.06%
controls:2.24%
—
—
—
—
cases:2.59%
controls:0.52%
cases:8.26%
controls:2.66%
cases:15.69%
controls:5.97%
65
185
283
3295
35
78
313
3402
—
—
9
18
339
3457
28
90
311
3288
43
162
231
2552
Psychologist
Z2445 [2001311558]
Z2445 [2001311558]
2.0e+00
—
—
—
—
2.3e+00
2.5e+00
cases:4.89%
controls:0.69%
—
—
—
—
—
—
—
—
cases:2.65%
controls:0.27%
cases:4.01%
controls:0.33%
17
24
331
3456
—
—
—
—
9
9
330
3369
11
9
263
2705
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
8099-4 [3027238]
1.8e+00
2.2e+00
—
—
—
1.5e+00
1.3e+00
cases:14.08%
controls:2.61%
cases:8.05%
controls:1.01%
—
—
—
—
—
—
cases:3.83%
controls:0.86%
cases:10.58%
controls:3.28%
49
91
299
3389
28
35
320
3445
—
—
—
13
29
326
3349
29
89
245
2625
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
1.6e+00
1.7e+00
—
—
2.3e+00
1.8e+00
1.5e+00
cases:11.21%
controls:2.44%
cases:7.47%
controls:1.41%
—
—
—
—
cases:1.44%
controls:0.14%
cases:6.49%
controls:1.15%
cases:16.42%
controls:4.13%
39
85
309
3395
26
49
322
3431
—
—
5
5
343
3470
22
39
317
3339
45
112
229
2602
Recurrent depression, moderate episode without somatic syndrome
F33.10 [2000501984]
F33.10 [2000501984]
1.6e+00
1.6e+00
—
1.0e+50
—
1.9e+00
1.6e+00
cases:5.75%
controls:1.26%
cases:3.45%
controls:0.72%
—
—
cases:1.44%
controls:0.00%
—
—
cases:5.01%
controls:0.77%
cases:9.85%
controls:2.21%
20
44
328
3436
12
25
336
3455
—
5
0
343
3480
—
17
26
322
3352
27
60
247
2654
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
5128-4 [3001334]
1.9e+00
3.0e+00
—
—
—
—
1.8e+00
cases:4.89%
controls:0.75%
cases:3.74%
controls:0.20%
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.52%
17
26
331
3454
13
7
335
3473
—
—
—
—
8
14
266
2700
Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5253-0 [3027545]
5253-0 [3027545]
1.9e+00
3.0e+00
1.0e+50
—
—
—
1.6e+00
cases:7.18%
controls:1.12%
cases:5.17%
controls:0.26%
cases:1.44%
controls:0.00%
—
—
—
—
—
—
cases:4.38%
controls:0.92%
25
39
323
3441
18
9
330
3471
5
0
343
3480
—
—
—
12
25
262
2689
Paediatric neurology
421 [44777781]
421 [44777781]
—
2.0e+00
—
—
—
2.5e+00
2.1e+00
—
—
cases:1.72%
controls:0.23%
—
—
—
—
—
—
cases:2.36%
controls:0.21%
cases:2.55%
controls:0.33%
—
6
8
342
3472
—
—
—
8
7
331
3371
7
9
267
2705
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
14920-3 [3008486]
1.0e+00
1.1e+00
1.6e+00
—
1.2e+00
6.8e-01
9.3e-01
cases:54.31%
controls:30.43%
cases:38.22%
controls:16.55%
cases:9.77%
controls:2.21%
—
—
cases:6.61%
controls:2.13%
cases:27.43%
controls:16.02%
cases:62.41%
controls:39.46%
189
1059
159
2421
133
576
215
2904
34
77
314
3403
—
23
74
325
3401
93
541
246
2837
171
1071
103
1643
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
1.9e+00
2.3e+00
—
—
—
2.3e+00
1.5e+00
cases:2.87%
controls:0.46%
cases:2.30%
controls:0.23%
—
—
—
—
—
—
cases:1.77%
controls:0.18%
cases:2.92%
controls:0.66%
10
16
338
3464
8
8
340
3472
—
—
—
6
6
333
3372
8
18
266
2696
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
9.6e-01
1.1e+00
1.3e+00
—
1.6e+00
1.5e+00
1.3e+00
cases:14.66%
controls:6.18%
cases:9.20%
controls:3.33%
cases:2.30%
controls:0.63%
—
—
cases:3.16%
controls:0.63%
cases:12.09%
controls:2.99%
cases:21.53%
controls:6.85%
51
215
297
3265
32
116
316
3364
8
22
340
3458
—
11
22
337
3453
41
101
298
3277
59
186
215
2528
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
9.0e-01
1.2e+00
1.6e+00
—
1.2e+00
7.4e-01
8.5e-01
cases:58.62%
controls:36.52%
cases:47.41%
controls:21.09%
cases:11.78%
controls:2.64%
—
—
cases:8.33%
controls:2.73%
cases:35.99%
controls:21.11%
cases:68.61%
controls:48.27%
204
1271
144
2209
165
734
183
2746
41
92
307
3388
—
29
95
319
3380
122
713
217
2665
188
1310
86
1404
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
F32.2 [45557202]
1.5e+00
1.6e+00
—
—
2.0e+00
2.0e+00
1.3e+00
cases:5.46%
controls:1.32%
cases:3.45%
controls:0.69%
—
—
—
—
cases:1.44%
controls:0.20%
cases:4.13%
controls:0.56%
cases:6.20%
controls:1.81%
19
46
329
3434
12
24
336
3456
—
—
5
7
343
3468
14
19
325
3359
17
49
257
2665
ranitidine bismuth citrate; oral
A02BA07 [21600088]
A02BA07 [21600088]
1.7e+00
2.3e+00
—
—
—
—
2.3e+00
cases:5.75%
controls:1.06%
cases:1.72%
controls:0.17%
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.33%
20
37
328
3443
6
6
342
3474
—
—
—
—
9
9
265
2705
ranitidine; oral, parenteral
A02BA02 [21600083]
A02BA02 [21600083]
1.7e+00
2.3e+00
—
—
—
—
2.3e+00
cases:5.75%
controls:1.06%
cases:1.72%
controls:0.17%
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.33%
20
37
328
3443
6
6
342
3474
—
—
—
—
9
9
265
2705
Pain, unspecified
R52.9 [45544151]
R52.9 [45544151]
1.3e+00
1.7e+00
—
—
—
1.8e+00
1.5e+00
cases:4.02%
controls:1.09%
cases:2.30%
controls:0.43%
—
—
—
—
—
—
cases:2.06%
controls:0.36%
cases:6.93%
controls:1.58%
14
38
334
3442
8
15
340
3465
—
—
—
7
12
332
3366
19
43
255
2671
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
1.0e+00
1.5e+00
—
—
1.9e+00
1.1e+00
8.3e-01
cases:15.23%
controls:6.21%
cases:11.78%
controls:2.93%
—
—
—
—
cases:2.01%
controls:0.32%
cases:7.08%
controls:2.40%
cases:17.15%
controls:8.25%
53
216
295
3264
41
102
307
3378
—
—
7
11
341
3464
24
81
315
3297
47
224
227
2490
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
1.1e+00
1.5e+00
1.5e+00
—
1.2e+00
1.2e+00
9.5e-01
cases:22.99%
controls:9.45%
cases:18.97%
controls:4.86%
cases:3.45%
controls:0.78%
—
—
cases:2.59%
controls:0.78%
cases:14.16%
controls:4.71%
cases:24.09%
controls:10.94%
80
329
268
3151
66
169
282
3311
12
27
336
3453
—
9
27
339
3448
48
159
291
3219
66
297
208
2417
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
1.4e+00
1.5e+00
2.0e+00
—
1.7e+00
9.1e-01
1.4e+00
cases:19.54%
controls:5.72%
cases:12.07%
controls:2.96%
cases:2.59%
controls:0.37%
—
—
cases:2.01%
controls:0.37%
cases:5.01%
controls:2.07%
cases:22.26%
controls:6.85%
68
199
280
3281
42
103
306
3377
9
13
339
3467
—
7
13
341
3462
17
70
322
3308
61
186
213
2528
Dizziness and giddiness
R42 [45568132]
R42 [45568132]
1.7e+00
2.1e+00
—
—
2.3e+00
1.4e+00
9.9e-01
cases:9.48%
controls:1.95%
cases:6.03%
controls:0.75%
—
—
—
—
cases:1.44%
controls:0.14%
cases:2.95%
controls:0.74%
cases:7.30%
controls:2.84%
33
68
315
3412
21
26
327
3454
—
—
5
5
343
3470
10
25
329
3353
20
77
254
2637
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
3.6e-01
8.6e-01
1.4e+00
1.6e+00
9.5e-01
7.0e-01
6.1e-01
cases:62.07%
controls:53.22%
cases:59.48%
controls:38.39%
cases:24.71%
controls:7.24%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.71%
cases:56.64%
controls:39.25%
cases:81.02%
controls:69.93%
216
1852
132
1628
207
1336
141
2144
86
252
262
3228
8
16
340
3464
62
268
286
3207
192
1326
147
2052
222
1898
52
816
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
3.6e-01
8.5e-01
1.4e+00
1.6e+00
9.6e-01
7.0e-01
6.1e-01
cases:62.07%
controls:53.25%
cases:59.48%
controls:38.51%
cases:24.71%
controls:7.21%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.68%
cases:56.64%
controls:39.37%
cases:81.02%
controls:69.93%
216
1853
132
1627
207
1340
141
2140
86
251
262
3229
8
16
340
3464
62
267
286
3208
192
1330
147
2048
222
1898
52
816
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
3.6e-01
8.5e-01
1.4e+00
1.6e+00
9.5e-01
7.1e-01
6.0e-01
cases:62.07%
controls:53.28%
cases:59.48%
controls:38.48%
cases:24.71%
controls:7.24%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.71%
cases:56.93%
controls:39.40%
cases:81.02%
controls:70.12%
216
1854
132
1626
207
1339
141
2141
86
252
262
3228
8
16
340
3464
62
268
286
3207
193
1331
146
2047
222
1903
52
811
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
3.6e-01
8.5e-01
1.4e+00
1.6e+00
9.5e-01
7.0e-01
6.0e-01
cases:62.07%
controls:53.22%
cases:59.48%
controls:38.51%
cases:24.71%
controls:7.24%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.71%
cases:56.64%
controls:39.34%
cases:81.02%
controls:70.08%
216
1852
132
1628
207
1340
141
2140
86
252
262
3228
8
16
340
3464
62
268
286
3207
192
1329
147
2049
222
1902
52
812
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
3.6e-01
8.5e-01
1.4e+00
1.6e+00
9.5e-01
7.0e-01
6.0e-01
cases:62.07%
controls:53.25%
cases:59.48%
controls:38.51%
cases:24.71%
controls:7.24%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.71%
cases:56.64%
controls:39.40%
cases:81.02%
controls:70.12%
216
1853
132
1627
207
1340
141
2140
86
252
262
3228
8
16
340
3464
62
268
286
3207
192
1331
147
2047
222
1903
52
811
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
3.6e-01
8.5e-01
1.4e+00
1.6e+00
9.6e-01
6.9e-01
6.0e-01
cases:62.07%
controls:53.33%
cases:59.48%
controls:38.56%
cases:24.71%
controls:7.24%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.68%
cases:56.64%
controls:39.49%
cases:81.02%
controls:70.15%
216
1856
132
1624
207
1342
141
2138
86
252
262
3228
8
16
340
3464
62
267
286
3208
192
1334
147
2044
222
1904
52
810
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
3.6e-01
8.5e-01
1.4e+00
1.6e+00
9.4e-01
7.1e-01
5.9e-01
cases:62.07%
controls:53.36%
cases:59.48%
controls:38.51%
cases:24.71%
controls:7.24%
cases:2.30%
controls:0.46%
cases:17.82%
controls:7.80%
cases:56.93%
controls:39.49%
cases:81.02%
controls:70.19%
216
1857
132
1623
207
1340
141
2140
86
252
262
3228
8
16
340
3464
62
271
286
3204
193
1334
146
2044
222
1905
52
809
Hypermobility syndrome
M35.7 [45601437]
M35.7 [45601437]
2.8e+00
—
—
1.0e+50
1.0e+50
—
3.3e+00
cases:3.74%
controls:0.23%
—
—
—
—
cases:2.01%
controls:0.00%
cases:1.72%
controls:0.00%
—
—
cases:5.84%
controls:0.22%
13
8
335
3472
—
—
7
0
341
3480
6
0
342
3475
—
16
6
258
2708
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
19113-0 [3005322]
1.0e+00
2.0e+00
—
—
—
1.6e+00
1.5e+00
cases:6.03%
controls:2.27%
cases:3.74%
controls:0.52%
—
—
—
—
—
—
cases:3.54%
controls:0.71%
cases:8.39%
controls:2.03%
21
79
327
3401
13
18
335
3462
—
—
—
12
24
327
3354
23
55
251
2659
FEV1
20150-9 [3024653]
20150-9 [3024653]
1.3e+00
1.7e+00
—
—
—
2.3e+00
2.5e+00
cases:5.17%
controls:1.41%
cases:1.44%
controls:0.26%
—
—
—
—
—
—
cases:3.24%
controls:0.33%
cases:6.57%
controls:0.59%
18
49
330
3431
5
9
343
3471
—
—
—
11
11
328
3367
18
16
256
2698
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
1.3e+00
1.7e+00
—
—
—
2.3e+00
2.5e+00
cases:5.17%
controls:1.41%
cases:1.44%
controls:0.26%
—
—
—
—
—
—
cases:3.24%
controls:0.33%
cases:6.57%
controls:0.59%
18
49
330
3431
5
9
343
3471
—
—
—
11
11
328
3367
18
16
256
2698
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
1.3e+00
1.7e+00
—
—
—
2.3e+00
2.5e+00
cases:5.17%
controls:1.41%
cases:1.44%
controls:0.26%
—
—
—
—
—
—
cases:3.24%
controls:0.33%
cases:6.57%
controls:0.59%
18
49
330
3431
5
9
343
3471
—
—
—
11
11
328
3367
18
16
256
2698
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
F32.10 [2000501980]
1.4e+00
1.2e+00
—
—
2.0e+00
1.5e+00
1.2e+00
cases:6.90%
controls:1.75%
cases:3.16%
controls:0.95%
—
—
—
—
cases:1.72%
controls:0.23%
cases:3.24%
controls:0.77%
cases:6.57%
controls:2.03%
24
61
324
3419
11
33
337
3447
—
—
6
8
342
3467
11
26
328
3352
18
55
256
2659
agomelatine; oral
N06AX22 [21604750]
N06AX22 [21604750]
1.6e+00
2.2e+00
—
—
—
—
2.3e+00
cases:3.16%
controls:0.66%
cases:1.72%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.65%
controls:0.37%
11
23
337
3457
6
7
342
3473
—
—
—
—
10
10
264
2704
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
29265-6 [3020059]
1.2e+00
2.2e+00
—
—
—
1.7e+00
9.3e-01
cases:9.48%
controls:2.96%
cases:7.18%
controls:0.83%
—
—
—
—
—
—
cases:4.42%
controls:0.86%
cases:9.12%
controls:3.80%
33
103
315
3377
25
29
323
3451
—
—
—
15
29
324
3349
25
103
249
2611
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
1.9e+00
2.2e+00
—
—
—
1.9e+00
1.3e+00
cases:5.17%
controls:0.80%
cases:2.59%
controls:0.29%
—
—
—
—
—
—
cases:2.06%
controls:0.33%
cases:2.92%
controls:0.77%
18
28
330
3452
9
10
339
3470
—
—
—
7
11
332
3367
8
21
266
2693
modafinil; oral
N06BA07 [21604760]
N06BA07 [21604760]
3.0e+00
—
—
—
—
2.9e+00
—
cases:2.87%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.65%
controls:0.15%
—
—
10
5
338
3475
—
—
—
—
9
5
330
3373
—
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
Z03.9 [45552062]
9.4e-01
1.8e+00
1.0e+50
—
—
1.9e+00
1.2e+00
cases:7.47%
controls:3.05%
cases:5.75%
controls:0.98%
cases:1.44%
controls:0.00%
—
—
—
—
cases:5.01%
controls:0.77%
cases:7.66%
controls:2.36%
26
106
322
3374
20
34
328
3446
5
0
343
3480
—
—
17
26
322
3352
21
64
253
2650
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
7.2e-01
6.8e-01
1.6e+00
—
1.8e+00
7.5e-01
1.0e+00
cases:18.10%
controls:9.74%
cases:8.62%
controls:4.57%
cases:2.30%
controls:0.46%
—
—
cases:2.30%
controls:0.40%
cases:8.55%
controls:4.23%
cases:26.28%
controls:11.42%
63
339
285
3141
30
159
318
3321
8
16
340
3464
—
8
14
340
3461
29
143
310
3235
72
310
202
2404
methylphenidate; oral
N06BA04 [21604757]
N06BA04 [21604757]
1.3e+00
1.6e+00
—
—
—
1.3e+00
1.7e+00
cases:3.45%
controls:1.01%
cases:3.74%
controls:0.78%
—
—
—
—
—
—
cases:3.54%
controls:0.98%
cases:11.31%
controls:2.28%
12
35
336
3445
13
27
335
3453
—
—
—
12
33
327
3345
31
62
243
2652
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
14685-2 [3009035]
1.7e+00
1.9e+00
—
—
—
1.3e+00
9.2e-01
cases:16.38%
controls:3.48%
cases:8.62%
controls:1.38%
—
—
—
—
—
—
cases:5.60%
controls:1.54%
cases:12.04%
controls:5.16%
57
121
291
3359
30
48
318
3432
—
—
—
19
52
320
3326
33
140
241
2574
prednisone; oral
H02AB07 [21602735]
H02AB07 [21602735]
1.4e+00
2.5e+00
—
—
—
2.0e+00
9.2e-01
cases:3.16%
controls:0.80%
cases:2.01%
controls:0.17%
—
—
—
—
—
—
cases:2.06%
controls:0.30%
cases:2.19%
controls:0.88%
11
28
337
3452
7
6
341
3474
—
—
—
7
10
332
3368
6
24
268
2690
prednisone
A07EA03 [21600655]
A07EA03 [21600655]
1.4e+00
2.5e+00
—
—
—
2.0e+00
9.2e-01
cases:3.16%
controls:0.80%
cases:2.01%
controls:0.17%
—
—
—
—
—
—
cases:2.06%
controls:0.30%
cases:2.19%
controls:0.88%
11
28
337
3452
7
6
341
3474
—
—
—
7
10
332
3368
6
24
268
2690
Social worker
Z2446 [2001311559]
Z2446 [2001311559]
1.3e+00
1.4e+00
—
—
—
2.5e+00
2.0e+00
cases:4.02%
controls:1.12%
cases:1.44%
controls:0.37%
—
—
—
—
—
—
cases:3.24%
controls:0.27%
cases:3.28%
controls:0.48%
14
39
334
3441
5
13
343
3467
—
—
—
11
9
328
3369
9
13
265
2701
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
5130-0 [3023420]
1.7e+00
2.4e+00
—
—
—
1.3e+00
1.6e+00
cases:4.60%
controls:0.86%
cases:4.60%
controls:0.43%
—
—
—
—
—
—
cases:1.77%
controls:0.47%
cases:5.11%
controls:1.11%
16
30
332
3450
16
15
332
3465
—
—
—
6
16
333
3362
14
30
260
2684
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
1.3e+00
2.0e+00
—
—
—
2.0e+00
2.3e+00
cases:4.60%
controls:1.29%
cases:1.44%
controls:0.20%
—
—
—
—
—
—
cases:2.36%
controls:0.33%
cases:5.84%
controls:0.59%
16
45
332
3435
5
7
343
3473
—
—
—
8
11
331
3367
16
16
258
2698
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
1.3e+00
2.0e+00
—
—
—
2.0e+00
2.3e+00
cases:4.60%
controls:1.29%
cases:1.44%
controls:0.20%
—
—
—
—
—
—
cases:2.36%
controls:0.33%
cases:5.84%
controls:0.59%
16
45
332
3435
5
7
343
3473
—
—
—
8
11
331
3367
16
16
258
2698
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
1.3e+00
2.0e+00
—
—
—
2.0e+00
2.3e+00
cases:4.60%
controls:1.29%
cases:1.44%
controls:0.20%
—
—
—
—
—
—
cases:2.36%
controls:0.33%
cases:5.84%
controls:0.59%
16
45
332
3435
5
7
343
3473
—
—
—
8
11
331
3367
16
16
258
2698
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
1.3e+00
2.0e+00
—
—
—
2.0e+00
2.3e+00
cases:4.60%
controls:1.29%
cases:1.44%
controls:0.20%
—
—
—
—
—
—
cases:2.36%
controls:0.33%
cases:5.84%
controls:0.59%
16
45
332
3435
5
7
343
3473
—
—
—
8
11
331
3367
16
16
258
2698
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
1.3e+00
2.0e+00
—
—
—
2.0e+00
2.3e+00
cases:4.60%
controls:1.29%
cases:1.44%
controls:0.20%
—
—
—
—
—
—
cases:2.36%
controls:0.33%
cases:5.84%
controls:0.59%
16
45
332
3435
5
7
343
3473
—
—
—
8
11
331
3367
16
16
258
2698
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
10704-5 [3003327]
1.6e+00
1.8e+00
—
—
—
2.2e+00
1.2e+00
cases:5.17%
controls:1.09%
cases:2.30%
controls:0.40%
—
—
—
—
—
—
cases:2.36%
controls:0.27%
cases:4.01%
controls:1.25%
18
38
330
3442
8
14
340
3466
—
—
—
8
9
331
3369
11
34
263
2680
Recurrent depressive disorder, unspecified
F33.9 [45581458]
F33.9 [45581458]
1.8e+00
—
—
—
—
2.2e+00
1.6e+00
cases:4.02%
controls:0.69%
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.27%
cases:4.38%
controls:0.96%
14
24
334
3456
—
—
—
—
8
9
331
3369
12
26
262
2688
Gas panel - Central venous blood
97535-9 [1616796]
97535-9 [1616796]
2.6e+00
2.9e+00
—
—
—
—
1.6e+00
cases:5.17%
controls:0.40%
cases:3.16%
controls:0.17%
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.44%
18
14
330
3466
11
6
337
3474
—
—
—
—
6
12
268
2702
Migraine, unspecified
G43.9 [45595943]
G43.9 [45595943]
1.3e+00
1.4e+00
—
—
—
2.4e+00
1.8e+00
cases:6.61%
controls:1.84%
cases:2.59%
controls:0.63%
—
—
—
—
—
—
cases:3.83%
controls:0.36%
cases:10.95%
controls:2.03%
23
64
325
3416
9
22
339
3458
—
—
—
13
12
326
3366
30
55
244
2659
Person consulting for explanation of investigation findings
Z71.2 [45552100]
Z71.2 [45552100]
8.9e-01
1.2e+00
—
—
2.7e+00
2.0e-01
8.0e-01
cases:10.06%
controls:4.40%
cases:5.46%
controls:1.78%
—
—
—
—
cases:2.01%
controls:0.14%
cases:2.95%
controls:2.43%
cases:14.23%
controls:6.93%
35
153
313
3327
19
62
329
3418
—
—
7
5
341
3470
10
82
329
3296
39
188
235
2526
General Practice
1 [38004446]
1 [38004446]
8.4e-01
1.1e+00
1.8e+00
1.0e+50
1.3e+00
8.7e-01
8.9e-01
cases:22.99%
controls:11.41%
cases:10.92%
controls:3.97%
cases:2.01%
controls:0.34%
cases:3.45%
controls:0.00%
cases:1.44%
controls:0.40%
cases:7.96%
controls:3.49%
cases:20.07%
controls:9.36%
80
397
268
3083
38
138
310
3342
7
12
341
3468
12
0
336
3480
5
14
343
3461
27
118
312
3260
55
254
219
2460
Emergency Room Visit
ER [9203]
ER [9203]
6.1e-01
9.0e-01
1.2e+00
—
1.3e+00
7.5e-01
7.1e-01
cases:49.43%
controls:34.68%
cases:20.98%
controls:9.71%
cases:3.74%
controls:1.18%
—
—
cases:4.31%
controls:1.21%
cases:16.22%
controls:8.41%
cases:36.50%
controls:22.03%
172
1207
176
2273
73
338
275
3142
13
41
335
3439
—
15
42
333
3433
55
284
284
3094
100
598
174
2116
Snapping jaw
K07.60 [2000502791]
K07.60 [2000502791]
9.9e-01
1.8e+00
—
—
—
1.8e+00
1.9e+00
cases:2.59%
controls:0.98%
cases:2.30%
controls:0.40%
—
—
—
—
—
—
cases:2.36%
controls:0.41%
cases:6.93%
controls:1.07%
9
34
339
3446
8
14
340
3466
—
—
—
8
14
331
3364
19
29
255
2685
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
1.4e+00
1.2e+00
—
—
—
1.4e+00
1.6e+00
cases:9.48%
controls:2.64%
cases:4.89%
controls:1.58%
—
—
—
—
—
—
cases:5.60%
controls:1.51%
cases:16.79%
controls:3.98%
33
92
315
3388
17
55
331
3425
—
—
—
19
51
320
3327
46
108
228
2606
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
6.5e-01
9.2e-01
1.4e+00
—
1.0e+00
7.2e-01
7.4e-01
cases:57.47%
controls:41.41%
cases:47.99%
controls:26.84%
cases:16.38%
controls:4.60%
—
—
cases:11.49%
controls:4.52%
cases:43.66%
controls:27.47%
cases:73.72%
controls:57.22%
200
1441
148
2039
167
934
181
2546
57
160
291
3320
—
40
157
308
3318
148
928
191
2450
202
1553
72
1161
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
1.1e+00
9.8e-01
5.0e-01
—
1.3e+00
1.2e+00
8.9e-01
cases:18.10%
controls:6.84%
cases:13.51%
controls:5.55%
cases:2.30%
controls:1.41%
—
—
cases:4.02%
controls:1.18%
cases:16.22%
controls:5.48%
cases:18.25%
controls:8.40%
63
238
285
3242
47
193
301
3287
8
49
340
3431
—
14
41
334
3434
55
185
284
3193
50
228
224
2486
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
1.1e+00
1.4e+00
—
—
—
1.6e+00
1.3e+00
cases:10.06%
controls:3.62%
cases:4.31%
controls:1.15%
—
—
—
—
—
—
cases:3.83%
controls:0.77%
cases:9.49%
controls:2.69%
35
126
313
3354
15
40
333
3440
—
—
—
13
26
326
3352
26
73
248
2641
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
7.7e-01
1.2e+00
1.7e+00
—
1.5e+00
9.6e-01
9.6e-01
cases:14.66%
controls:7.36%
cases:10.92%
controls:3.45%
cases:2.01%
controls:0.37%
—
—
cases:2.59%
controls:0.60%
cases:10.03%
controls:4.09%
cases:23.36%
controls:10.46%
51
256
297
3224
38
120
310
3360
7
13
341
3467
—
9
21
339
3454
34
138
305
3240
64
284
210
2430
roxithromycin; oral
J01FA06 [21602974]
J01FA06 [21602974]
1.2e+00
2.1e+00
—
—
—
2.1e+00
8.4e-01
cases:8.05%
controls:2.50%
cases:3.16%
controls:0.40%
—
—
—
—
—
—
cases:2.06%
controls:0.27%
cases:4.01%
controls:1.77%
28
87
320
3393
11
14
337
3466
—
—
—
7
9
332
3369
11
48
263
2666
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
1.1e+00
1.3e+00
—
—
—
2.4e+00
1.9e+00
cases:6.90%
controls:2.41%
cases:2.01%
controls:0.57%
—
—
—
—
—
—
cases:4.42%
controls:0.41%
cases:5.47%
controls:0.88%
24
84
324
3396
7
20
341
3460
—
—
—
15
14
324
3364
15
24
259
2690
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
31017-7 [3019050]
9.3e-01
1.4e+00
2.3e+00
—
—
7.2e-01
6.9e-01
cases:19.54%
controls:8.76%
cases:10.06%
controls:2.64%
cases:2.30%
controls:0.23%
—
—
—
—
cases:5.60%
controls:2.81%
cases:16.79%
controls:9.17%
68
305
280
3175
35
92
313
3388
8
8
340
3472
—
—
19
95
320
3283
46
249
228
2465
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
1.3e+00
1.5e+00
—
—
—
1.2e+00
1.4e+00
cases:14.66%
controls:4.48%
cases:5.75%
controls:1.38%
—
—
—
—
—
—
cases:4.42%
controls:1.42%
cases:15.69%
controls:4.50%
51
156
297
3324
20
48
328
3432
—
—
—
15
48
324
3330
43
122
231
2592
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
5.4e-01
8.2e-01
1.5e+00
1.6e+00
1.1e+00
7.6e-01
6.2e-01
cases:48.85%
controls:35.66%
cases:43.39%
controls:25.26%
cases:18.97%
controls:4.97%
cases:1.44%
controls:0.29%
cases:13.22%
controls:4.98%
cases:41.59%
controls:25.07%
cases:63.50%
controls:48.23%
170
1241
178
2239
151
879
197
2601
66
173
282
3307
5
10
343
3470
46
173
302
3302
141
847
198
2531
174
1309
100
1405
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
7852-7 [3010130]
2.1e+00
3.2e+00
—
—
—
1.6e+00
1.6e+00
cases:6.90%
controls:0.89%
cases:5.17%
controls:0.23%
—
—
—
—
—
—
cases:2.06%
controls:0.41%
cases:2.92%
controls:0.63%
24
31
324
3449
18
8
330
3472
—
—
—
7
14
332
3364
8
17
266
2697
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
1.5e-01
5.0e-01
1.1e+00
2.1e+00
8.4e-01
6.2e-01
2.4e-01
cases:64.66%
controls:61.15%
cases:66.09%
controls:54.28%
cases:36.21%
controls:15.34%
cases:7.18%
controls:0.92%
cases:29.89%
controls:15.54%
cases:69.91%
controls:55.51%
cases:82.85%
controls:79.15%
225
2128
123
1352
230
1889
118
1591
126
534
222
2946
25
32
323
3448
104
540
244
2935
237
1875
102
1503
227
2148
47
566
hydroxocobalamin; parenteral
B03BA03 [21601123]
B03BA03 [21601123]
1.6e+00
1.7e+00
—
—
—
1.7e+00
1.8e+00
cases:2.30%
controls:0.49%
cases:2.30%
controls:0.43%
—
—
—
—
—
—
cases:2.65%
controls:0.50%
cases:3.28%
controls:0.55%
8
17
340
3463
8
15
340
3465
—
—
—
9
17
330
3361
9
15
265
2699
hydroxocobalamin
V03AB33 [21605256]
V03AB33 [21605256]
1.6e+00
1.7e+00
—
—
—
1.7e+00
1.8e+00
cases:2.30%
controls:0.49%
cases:2.30%
controls:0.43%
—
—
—
—
—
—
cases:2.65%
controls:0.50%
cases:3.28%
controls:0.55%
8
17
340
3463
8
15
340
3465
—
—
—
9
17
330
3361
9
15
265
2699
pH of Blood
11558-4 [3010421]
11558-4 [3010421]
2.5e+00
2.7e+00
—
—
—
—
1.5e+00
cases:5.46%
controls:0.46%
cases:2.01%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.52%
19
16
329
3464
7
5
341
3475
—
—
—
—
6
14
268
2700
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
N05BA06 [21604571]
1.5e+00
1.8e+00
—
—
—
1.9e+00
8.8e-01
cases:3.16%
controls:0.75%
cases:2.01%
controls:0.34%
—
—
—
—
—
—
cases:2.06%
controls:0.33%
cases:2.19%
controls:0.92%
11
26
337
3454
7
12
341
3468
—
—
—
7
11
332
3367
6
25
268
2689
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
26465-5 [3016543]
2.5e+00
2.6e+00
—
—
—
—
—
cases:7.47%
controls:0.66%
cases:2.30%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
26
23
322
3457
8
6
340
3474
—
—
—
—
—
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
26454-9 [3027475]
2.5e+00
2.6e+00
—
—
—
—
—
cases:7.47%
controls:0.66%
cases:2.30%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
26
23
322
3457
8
6
340
3474
—
—
—
—
—
Lumbar puncture
TAB00 [2001300538]
TAB00 [2001300538]
2.6e+00
—
—
—
—
—
2.5e+00
cases:5.75%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.26%
20
15
328
3465
—
—
—
—
—
8
7
266
2707
Migraine with aura [classical migraine]
G43.1 [45562086]
G43.1 [45562086]
1.3e+00
1.5e+00
—
1.0e+50
2.0e+00
1.3e+00
9.2e-01
cases:6.61%
controls:1.87%
cases:4.31%
controls:1.03%
—
—
cases:2.30%
controls:0.00%
cases:1.44%
controls:0.20%
cases:3.54%
controls:0.95%
cases:6.93%
controls:2.87%
23
65
325
3415
15
36
333
3444
—
8
0
340
3480
5
7
343
3468
12
32
327
3346
19
78
255
2636
melatonin; oral
N05CH01 [21604659]
N05CH01 [21604659]
1.2e+00
1.4e+00
1.3e+00
—
1.1e+00
1.5e+00
9.8e-01
cases:11.78%
controls:4.05%
cases:9.20%
controls:2.44%
cases:2.01%
controls:0.55%
—
—
cases:1.72%
controls:0.58%
cases:10.62%
controls:2.61%
cases:14.96%
controls:6.19%
41
141
307
3339
32
85
316
3395
7
19
341
3461
—
6
20
342
3455
36
88
303
3290
41
168
233
2546
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
8.9e-01
1.1e+00
—
—
1.4e+00
1.8e+00
1.2e+00
cases:18.10%
controls:8.33%
cases:6.32%
controls:2.27%
—
—
—
—
cases:1.44%
controls:0.35%
cases:10.32%
controls:1.81%
cases:13.14%
controls:4.38%
63
290
285
3190
22
79
326
3401
—
—
5
12
343
3463
35
61
304
3317
36
119
238
2595
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 [3020044]
14744-7 [3020044]
2.5e+00
2.5e+00
—
—
—
—
—
cases:7.18%
controls:0.63%
cases:2.30%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
25
22
323
3458
8
7
340
3473
—
—
—
—
—
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
2880-3 [3019473]
2.5e+00
2.5e+00
—
—
—
—
—
cases:7.76%
controls:0.69%
cases:2.30%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
27
24
321
3456
8
7
340
3473
—
—
—
—
—
Cardiac arrhythmia, unspecified
I49.9 [45581778]
I49.9 [45581778]
1.4e+00
1.8e+00
—
—
—
1.7e+00
6.0e-01
cases:5.17%
controls:1.26%
cases:3.45%
controls:0.60%
—
—
—
—
—
—
cases:2.36%
controls:0.44%
cases:4.01%
controls:2.25%
18
44
330
3436
12
21
336
3459
—
—
—
8
15
331
3363
11
61
263
2653
Other specified extrapyramidal and movement disorders
G25.8 [45542878]
G25.8 [45542878]
—
—
—
1.0e+50
—
2.5e+00
2.4e+00
—
—
—
—
—
—
cases:1.72%
controls:0.00%
—
—
cases:2.06%
controls:0.18%
cases:4.38%
controls:0.41%
—
—
—
6
0
342
3480
—
7
6
332
3372
12
11
262
2703
Rheumatology
66 [38004491]
66 [38004491]
1.3e+00
1.2e+00
1.2e+00
—
7.8e-01
1.3e+00
1.1e+00
cases:12.36%
controls:3.85%
cases:8.05%
controls:2.61%
cases:1.72%
controls:0.52%
—
—
cases:1.44%
controls:0.66%
cases:7.96%
controls:2.31%
cases:13.50%
controls:4.79%
43
134
305
3346
28
91
320
3389
6
18
342
3462
—
5
23
343
3452
27
78
312
3300
37
130
237
2584
salbutamol; inhalant
R03AC02 [21603256]
R03AC02 [21603256]
9.8e-01
1.1e+00
1.2e+00
—
9.6e-01
8.5e-01
7.8e-01
cases:36.49%
controls:17.73%
cases:20.69%
controls:8.36%
cases:5.46%
controls:1.72%
—
—
cases:3.74%
controls:1.47%
cases:16.52%
controls:7.79%
cases:33.21%
controls:18.50%
127
617
221
2863
72
291
276
3189
19
60
329
3420
—
13
51
335
3424
56
263
283
3115
91
502
183
2212
salmeterol and fluticasone
R03AK06 [21603280]
R03AK06 [21603280]
9.5e-01
1.5e+00
—
—
1.4e+00
1.2e+00
1.2e+00
cases:4.89%
controls:1.95%
cases:4.89%
controls:1.15%
—
—
—
—
cases:1.44%
controls:0.37%
cases:3.54%
controls:1.07%
cases:6.20%
controls:1.95%
17
68
331
3412
17
40
331
3440
—
—
5
13
343
3462
12
36
327
3342
17
53
257
2661
Dry eye syndrome
H04.10 [2000502254]
H04.10 [2000502254]
1.5e+00
1.9e+00
—
1.0e+50
—
1.5e+00
7.4e-01
cases:5.17%
controls:1.24%
cases:4.31%
controls:0.66%
—
—
cases:1.72%
controls:0.00%
—
—
cases:3.24%
controls:0.77%
cases:5.47%
controls:2.69%
18
43
330
3437
15
23
333
3457
—
6
0
342
3480
—
11
26
328
3352
15
73
259
2641
EKG study
11524-6 [3013512]
11524-6 [3013512]
9.2e-01
1.1e+00
2.2e+00
—
1.5e+00
5.8e-01
6.6e-01
cases:12.07%
controls:5.20%
cases:7.76%
controls:2.70%
cases:1.72%
controls:0.20%
—
—
cases:1.72%
controls:0.37%
cases:3.83%
controls:2.19%
cases:13.87%
controls:7.70%
42
181
306
3299
27
94
321
3386
6
7
342
3473
—
6
13
342
3462
13
74
326
3304
38
209
236
2505
Dedicated profession-specific psychiatric intervention, individual
IEY05 [2001304224]
IEY05 [2001304224]
1.2e+00
1.5e+00
—
—
—
1.7e+00
1.6e+00
cases:2.87%
controls:0.92%
cases:3.16%
controls:0.72%
—
—
—
—
—
—
cases:3.24%
controls:0.59%
cases:6.57%
controls:1.40%
10
32
338
3448
11
25
337
3455
—
—
—
11
20
328
3358
18
38
256
2676
Assessment of need for aid
SPAT1229 [2001700330]
SPAT1229 [2001700330]
1.4e+00
—
—
—
—
2.5e+00
2.3e+00
cases:1.72%
controls:0.43%
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.15%
cases:4.38%
controls:0.44%
6
15
342
3465
—
—
—
—
6
5
333
3373
12
12
262
2702
Centromere protein B Ab [Units/volume] in Serum
53982-5 [3039162]
53982-5 [3039162]
2.3e+00
2.5e+00
—
—
—
—
—
cases:2.87%
controls:0.29%
cases:1.72%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
10
10
338
3470
6
5
342
3475
—
—
—
—
—
Rheumatism, unspecified
M79.0 [45567658]
M79.0 [45567658]
2.3e+00
—
—
—
—
—
2.5e+00
cases:2.87%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.18%
10
10
338
3470
—
—
—
—
—
6
5
268
2709
Emotionally unstable personality disorder, borderline condition
F60.31 [2000502023]
F60.31 [2000502023]
2.3e+00
—
—
—
—
2.5e+00
—
cases:2.01%
controls:0.20%
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.15%
—
—
7
7
341
3473
—
—
—
—
6
5
333
3373
—
U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum
59026-5 [40762119]
59026-5 [40762119]
2.5e+00
2.3e+00
—
—
—
—
—
cases:2.30%
controls:0.20%
cases:2.01%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
8
7
340
3473
7
7
341
3473
—
—
—
—
—
Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
5257-1 [3010521]
5257-1 [3010521]
1.8e+00
2.9e+00
1.0e+50
—
—
—
1.3e+00
cases:6.03%
controls:1.03%
cases:4.02%
controls:0.23%
cases:1.44%
controls:0.00%
—
—
—
—
—
—
cases:2.92%
controls:0.77%
21
36
327
3444
14
8
334
3472
5
0
343
3480
—
—
—
8
21
266
2693
Hospital outpatient
ZY010 [2001311599]
ZY010 [2001311599]
1.3e+00
1.2e+00
—
—
—
1.5e+00
1.9e+00
cases:5.75%
controls:1.64%
cases:2.59%
controls:0.78%
—
—
—
—
—
—
cases:2.65%
controls:0.59%
cases:5.84%
controls:0.92%
20
57
328
3423
9
27
339
3453
—
—
—
9
20
330
3358
16
25
258
2689
Base excess in Blood by calculation
11555-0 [3012501]
11555-0 [3012501]
2.5e+00
—
—
—
—
—
2.2e+00
cases:5.46%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.26%
19
16
329
3464
—
—
—
—
—
6
7
268
2707
Carbon dioxide [Partial pressure] in Blood
11557-6 [3013290]
11557-6 [3013290]
2.5e+00
—
—
—
—
—
2.2e+00
cases:5.46%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.26%
19
16
329
3464
—
—
—
—
—
6
7
268
2707
Ileoscopy through colon
UJF30 [2001305028]
UJF30 [2001305028]
1.3e+00
—
—
—
—
2.0e+00
1.4e+00
cases:5.17%
controls:1.41%
—
—
—
—
—
—
—
—
cases:3.24%
controls:0.47%
cases:4.01%
controls:1.07%
18
49
330
3431
—
—
—
—
11
16
328
3362
11
29
263
2685
Participation in compiling a psychiatric treatment plan
ICZ03 [2001304119]
ICZ03 [2001304119]
1.3e+00
1.1e+00
—
—
—
1.9e+00
1.4e+00
cases:3.74%
controls:1.01%
cases:1.72%
controls:0.60%
—
—
—
—
—
—
cases:2.95%
controls:0.44%
cases:4.38%
controls:1.14%
13
35
335
3445
6
21
342
3459
—
—
—
10
15
329
3363
12
31
262
2683
Oxygen [Partial pressure] in Blood
11556-8 [3027315]
11556-8 [3027315]
2.5e+00
—
—
—
—
—
2.2e+00
cases:5.17%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.26%
18
16
330
3464
—
—
—
—
—
6
7
268
2707
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
8.1e-01
9.9e-01
1.7e+00
—
1.1e+00
7.5e-01
1.1e+00
cases:15.52%
controls:7.56%
cases:9.48%
controls:3.76%
cases:2.59%
controls:0.49%
—
—
cases:2.30%
controls:0.81%
cases:6.78%
controls:3.32%
cases:21.17%
controls:8.03%
54
263
294
3217
33
131
315
3349
9
17
339
3463
—
8
28
340
3447
23
112
316
3266
58
218
216
2496
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
1.2e+00
1.3e+00
1.5e+00
—
1.4e+00
1.2e+00
9.6e-01
cases:17.53%
controls:6.01%
cases:9.20%
controls:2.73%
cases:1.44%
controls:0.32%
—
—
cases:1.44%
controls:0.37%
cases:8.26%
controls:2.75%
cases:19.34%
controls:8.40%
61
209
287
3271
32
95
316
3385
5
11
343
3469
—
5
13
343
3462
28
93
311
3285
53
228
221
2486
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
6.5e-01
6.4e-01
1.0e+00
—
1.2e+00
5.9e-01
4.7e-01
cases:46.55%
controls:31.35%
cases:25.57%
controls:15.40%
cases:4.31%
controls:1.64%
—
—
cases:5.46%
controls:1.73%
cases:24.78%
controls:15.42%
cases:51.82%
controls:40.13%
162
1091
186
2389
89
536
259
2944
15
57
333
3423
—
19
60
329
3415
84
521
255
2857
142
1089
132
1625
Psychiatric treatment plan, extended/prolonged
ICB02 [2001304099]
ICB02 [2001304099]
2.5e+00
-1.0e+50
—
—
—
—
2.1e+00
cases:2.30%
controls:0.20%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.55%
controls:0.33%
8
7
340
3473
0
5
348
3475
—
—
—
—
7
9
267
2705
Procedure duration 120 to 149 minutes
ZXE15 [2001311406]
ZXE15 [2001311406]
2.3e+00
2.3e+00
—
—
—
2.2e+00
—
cases:2.87%
controls:0.29%
cases:1.44%
controls:0.14%
—
—
—
—
—
—
cases:1.77%
controls:0.21%
—
—
10
10
338
3470
5
5
343
3475
—
—
—
6
7
333
3371
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
H03AA01 [21602754]
8.9e-01
7.8e-01
9.2e-01
—
6.0e-01
9.0e-01
9.6e-01
cases:21.26%
controls:9.94%
cases:18.68%
controls:9.51%
cases:5.46%
controls:2.24%
—
—
cases:5.46%
controls:3.08%
cases:20.65%
controls:9.56%
cases:25.55%
controls:11.64%
74
346
274
3134
65
331
283
3149
19
78
329
3402
—
19
107
329
3368
70
323
269
3055
70
316
204
2398
Gastroenterology
10 [38004455]
10 [38004455]
1.1e+00
8.4e-01
—
—
—
1.3e+00
1.2e+00
cases:14.66%
controls:5.32%
cases:6.03%
controls:2.70%
—
—
—
—
—
—
cases:9.44%
controls:2.78%
cases:16.79%
controls:5.86%
51
185
297
3295
21
94
327
3386
—
—
—
32
94
307
3284
46
159
228
2555
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
1.2e+00
1.3e+00
1.3e+00
—
—
8.0e-01
1.1e+00
cases:27.59%
controls:10.00%
cases:12.93%
controls:3.99%
cases:2.30%
controls:0.63%
—
—
—
—
cases:8.26%
controls:3.88%
cases:21.53%
controls:8.73%
96
348
252
3132
45
139
303
3341
8
22
340
3458
—
—
28
131
311
3247
59
237
215
2477
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
9.8e-01
9.4e-01
—
—
—
1.5e+00
9.5e-01
cases:18.39%
controls:7.82%
cases:6.32%
controls:2.56%
—
—
—
—
—
—
cases:10.32%
controls:2.55%
cases:14.60%
controls:6.19%
64
272
284
3208
22
89
326
3391
—
—
—
35
86
304
3292
40
168
234
2546
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
9.2e-01
1.6e+00
1.6e+00
—
1.5e+00
1.2e+00
7.1e-01
cases:33.33%
controls:16.67%
cases:15.80%
controls:3.79%
cases:2.01%
controls:0.40%
—
—
cases:2.01%
controls:0.46%
cases:12.39%
controls:4.20%
cases:24.82%
controls:14.00%
116
580
232
2900
55
132
293
3348
7
14
341
3466
—
7
16
341
3459
42
142
297
3236
68
380
206
2334
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
1.2e+00
1.3e+00
1.3e+00
—
—
8.0e-01
1.0e+00
cases:27.59%
controls:9.97%
cases:12.64%
controls:3.94%
cases:2.30%
controls:0.63%
—
—
—
—
cases:8.26%
controls:3.88%
cases:21.17%
controls:8.73%
96
347
252
3133
44
137
304
3343
8
22
340
3458
—
—
28
131
311
3247
58
237
216
2477
Otolaryngology
4 [38004449]
4 [38004449]
8.7e-01
1.3e+00
1.3e+00
—
1.4e+00
1.2e+00
9.7e-01
cases:20.11%
controls:9.51%
cases:12.36%
controls:3.65%
cases:1.72%
controls:0.46%
—
—
cases:2.01%
controls:0.49%
cases:9.14%
controls:3.05%
cases:20.44%
controls:8.84%
70
331
278
3149
43
127
305
3353
6
16
342
3464
—
7
17
341
3458
31
103
308
3275
56
240
218
2474
SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
26975-3 [3025245]
26975-3 [3025245]
1.9e+00
2.4e+00
—
—
—
1.5e+00
1.3e+00
cases:2.87%
controls:0.46%
cases:2.59%
controls:0.23%
—
—
—
—
—
—
cases:1.47%
controls:0.33%
cases:2.92%
controls:0.81%
10
16
338
3464
9
8
339
3472
—
—
—
5
11
334
3367
8
22
266
2692
CPAP therapy
WX723 [2001310826]
WX723 [2001310826]
—
2.7e+00
—
—
—
—
1.6e+00
—
—
cases:2.01%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.59%
—
7
5
341
3475
—
—
—
—
8
16
266
2698
Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum
7970-7 [3018387]
7970-7 [3018387]
1.5e+00
2.8e+00
—
—
—
—
1.5e+00
cases:3.45%
controls:0.80%
cases:2.30%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.52%
12
28
336
3452
8
5
340
3475
—
—
—
—
6
14
268
2700
Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Serum
17792-3 [3023939]
17792-3 [3023939]
1.8e+00
2.5e+00
—
—
—
—
1.4e+00
cases:2.87%
controls:0.49%
cases:2.01%
controls:0.17%
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.74%
10
17
338
3463
7
6
341
3474
—
—
—
—
8
20
266
2694
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
6968-2 [3009445]
1.8e+00
2.4e+00
—
—
—
—
1.4e+00
cases:4.31%
controls:0.72%
cases:2.87%
controls:0.26%
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.70%
15
25
333
3455
10
9
338
3471
—
—
—
—
8
19
266
2695
zolmitriptan; nasal, oral
N02CC03 [21604378]
N02CC03 [21604378]
1.1e+00
1.6e+00
—
—
-1.0e+50
9.7e-01
1.6e+00
cases:4.02%
controls:1.44%
cases:2.59%
controls:0.52%
—
—
—
—
cases:0.00%
controls:0.17%
cases:1.77%
controls:0.68%
cases:5.11%
controls:1.11%
14
50
334
3430
9
18
339
3462
—
—
0
6
348
3469
6
23
333
3355
14
30
260
2684
Post-traumatic stress disorder
F43.1 [45595909]
F43.1 [45595909]
1.5e+00
1.3e+00
—
—
—
2.2e+00
2.0e+00
cases:2.01%
controls:0.46%
cases:1.72%
controls:0.46%
—
—
—
—
—
—
cases:3.54%
controls:0.38%
cases:7.66%
controls:1.11%
7
16
341
3464
6
16
342
3464
—
—
—
12
13
327
3365
21
30
253
2684
Stomatognathic treatment, basic
SHA02 [2001310406]
SHA02 [2001310406]
1.1e+00
1.6e+00
—
—
—
1.4e+00
1.5e+00
cases:5.46%
controls:1.93%
cases:2.87%
controls:0.57%
—
—
—
—
—
—
cases:2.65%
controls:0.65%
cases:7.30%
controls:1.66%
19
67
329
3413
10
20
338
3460
—
—
—
9
22
330
3356
20
45
254
2669
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
8.1e-01
8.1e-01
1.3e+00
—
9.3e-01
6.8e-01
6.8e-01
cases:25.57%
controls:13.25%
cases:14.66%
controls:7.10%
cases:4.02%
controls:1.18%
—
—
cases:2.30%
controls:0.92%
cases:13.27%
controls:7.16%
cases:32.85%
controls:19.86%
89
461
259
3019
51
247
297
3233
14
41
334
3439
—
8
32
340
3443
45
242
294
3136
90
539
184
2175
Psychiatric treatment plan, monitoring
ICB03 [2001304100]
ICB03 [2001304100]
—
—
—
—
—
2.5e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:2.06%
controls:0.18%
cases:2.92%
controls:0.52%
—
—
—
—
—
7
6
332
3372
8
14
266
2700
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
8.4e-01
8.2e-01
1.2e+00
—
9.3e-01
6.8e-01
6.7e-01
cases:26.15%
controls:13.25%
cases:14.66%
controls:7.04%
cases:4.02%
controls:1.24%
—
—
cases:2.30%
controls:0.92%
cases:13.27%
controls:7.16%
cases:32.85%
controls:19.97%
91
461
257
3019
51
245
297
3235
14
43
334
3437
—
8
32
340
3443
45
242
294
3136
90
542
184
2172
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
9.0e-01
8.1e-01
1.1e+00
—
5.2e-01
7.6e-01
7.0e-01
cases:32.47%
controls:16.35%
cases:16.09%
controls:7.84%
cases:4.31%
controls:1.55%
—
—
cases:2.30%
controls:1.38%
cases:15.93%
controls:8.17%
cases:29.56%
controls:17.24%
113
569
235
2911
56
273
292
3207
15
54
333
3426
—
8
48
340
3427
54
276
285
3102
81
468
193
2246
Tension-type headache
G44.2 [45581495]
G44.2 [45581495]
1.3e+00
1.7e+00
—
—
—
1.2e+00
1.2e+00
cases:7.76%
controls:2.33%
cases:3.74%
controls:0.69%
—
—
—
—
—
—
cases:2.65%
controls:0.80%
cases:8.03%
controls:2.58%
27
81
321
3399
13
24
335
3456
—
—
—
9
27
330
3351
22
70
252
2644
hydrocortisone; oral, parenteral
H02AB09 [21602737]
H02AB09 [21602737]
1.2e+00
1.6e+00
—
—
—
1.9e+00
1.1e+00
cases:5.46%
controls:1.72%
cases:2.01%
controls:0.40%
—
—
—
—
—
—
cases:3.54%
controls:0.53%
cases:5.11%
controls:1.84%
19
60
329
3420
7
14
341
3466
—
—
—
12
18
327
3360
14
50
260
2664
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
113016006 [4010399]
9.9e-01
2.2e+00
—
—
—
9.6e-01
9.9e-01
cases:5.46%
controls:2.10%
cases:3.16%
controls:0.37%
—
—
—
—
—
—
cases:2.06%
controls:0.80%
cases:5.84%
controls:2.25%
19
73
329
3407
11
13
337
3467
—
—
—
7
27
332
3351
16
61
258
2653
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
48404-8 [3049804]
2.0e+00
2.2e+00
—
—
—
—
—
cases:3.16%
controls:0.46%
cases:2.01%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
11
16
337
3464
7
8
341
3472
—
—
—
—
—
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
G03BA03 [21602510]
2.0e+00
—
-1.0e+50
—
-1.0e+50
—
2.1e+00
cases:2.87%
controls:0.40%
—
—
cases:0.00%
controls:0.29%
—
—
cases:0.00%
controls:0.17%
—
—
cases:3.65%
controls:0.44%
10
14
338
3466
—
0
10
348
3470
—
0
6
348
3469
—
10
12
264
2702
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
7.9e-01
7.9e-01
1.2e+00
—
8.7e-01
6.6e-01
6.9e-01
cases:25.86%
controls:13.71%
cases:14.37%
controls:7.07%
cases:4.02%
controls:1.26%
—
—
cases:2.30%
controls:0.98%
cases:13.27%
controls:7.31%
cases:33.21%
controls:19.93%
90
477
258
3003
50
246
298
3234
14
44
334
3436
—
8
34
340
3441
45
247
294
3131
91
541
183
2173
Sprain and strain of cervical spine
S13.4 [45573197]
S13.4 [45573197]
2.1e+00
—
—
—
—
2.0e+00
1.1e+00
cases:2.01%
controls:0.26%
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.24%
cases:2.55%
controls:0.85%
7
9
341
3471
—
—
—
—
6
8
333
3370
7
23
267
2691
Chest pain, unspecified
R07.4 [45558450]
R07.4 [45558450]
1.0e+00
1.6e+00
—
—
—
1.4e+00
7.7e-01
cases:7.47%
controls:2.87%
cases:3.45%
controls:0.69%
—
—
—
—
—
—
cases:3.54%
controls:0.86%
cases:7.66%
controls:3.68%
26
100
322
3380
12
24
336
3456
—
—
—
12
29
327
3349
21
100
253
2614
Procedure duration 90 to 119 minutes
ZXE13 [2001311404]
ZXE13 [2001311404]
1.7e+00
1.6e+00
—
—
—
1.6e+00
2.3e+00
cases:4.60%
controls:0.83%
cases:1.44%
controls:0.29%
—
—
—
—
—
—
cases:1.77%
controls:0.36%
cases:4.38%
controls:0.44%
16
29
332
3451
5
10
343
3470
—
—
—
6
12
333
3366
12
12
262
2702
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
1.0e+00
1.0e+00
1.3e+00
—
1.3e+00
1.1e+00
9.5e-01
cases:18.10%
controls:7.30%
cases:8.91%
controls:3.42%
cases:2.01%
controls:0.57%
—
—
cases:1.44%
controls:0.40%
cases:8.26%
controls:3.05%
cases:18.25%
controls:7.96%
63
254
285
3226
31
119
317
3361
7
20
341
3460
—
5
14
343
3461
28
103
311
3275
50
216
224
2498
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
1.1e+00
1.1e+00
1.1e+00
—
1.1e+00
9.9e-01
8.9e-01
cases:21.26%
controls:8.39%
cases:9.77%
controls:3.51%
cases:2.01%
controls:0.66%
—
—
cases:1.44%
controls:0.49%
cases:8.55%
controls:3.37%
cases:17.52%
controls:8.03%
74
292
274
3188
34
122
314
3358
7
23
341
3457
—
5
17
343
3458
29
114
310
3264
48
218
226
2496
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
7.0e-01
1.1e+00
1.4e+00
—
9.9e-01
8.4e-01
3.6e-01
cases:29.02%
controls:16.81%
cases:14.08%
controls:5.37%
cases:4.02%
controls:0.98%
—
—
cases:2.59%
controls:0.98%
cases:12.68%
controls:5.92%
cases:19.71%
controls:14.66%
101
585
247
2895
49
187
299
3293
14
34
334
3446
—
9
34
339
3441
43
200
296
3178
54
398
220
2316
trazodone; oral
N06AX05 [21604734]
N06AX05 [21604734]
2.2e+00
—
—
—
—
—
1.8e+00
cases:2.30%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.48%
8
9
340
3471
—
—
—
—
—
8
13
266
2701
topiramate; oral
N03AX11 [21604433]
N03AX11 [21604433]
1.8e+00
1.8e+00
—
—
—
1.8e+00
2.2e+00
cases:2.87%
controls:0.49%
cases:1.72%
controls:0.29%
—
—
—
—
—
—
cases:1.47%
controls:0.24%
cases:3.28%
controls:0.37%
10
17
338
3463
6
10
342
3470
—
—
—
5
8
334
3370
9
10
265
2704
Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
35333-4 [3036086]
35333-4 [3036086]
1.8e+00
2.2e+00
—
—
—
—
1.3e+00
cases:2.87%
controls:0.49%
cases:2.30%
controls:0.26%
—
—
—
—
—
—
—
—
cases:2.55%
controls:0.70%
10
17
338
3463
8
9
340
3471
—
—
—
—
7
19
267
2695
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
7.7e-01
8.6e-01
1.3e+00
—
1.1e+00
5.9e-01
1.1e+00
cases:22.13%
controls:11.61%
cases:13.51%
controls:6.18%
cases:4.31%
controls:1.24%
—
—
cases:3.45%
controls:1.12%
cases:9.73%
controls:5.65%
cases:32.12%
controls:13.93%
77
404
271
3076
47
215
301
3265
15
43
333
3437
—
12
39
336
3436
33
191
306
3187
88
378
186
2336
Other migraine
G43.8 [45595941]
G43.8 [45595941]
2.1e+00
—
—
—
—
—
1.8e+00
cases:2.59%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.48%
9
11
339
3469
—
—
—
—
—
8
13
266
2701
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
9.9e-01
1.2e+00
—
—
1.4e+00
9.3e-01
8.4e-01
cases:19.25%
controls:8.13%
cases:10.63%
controls:3.53%
—
—
—
—
cases:2.30%
controls:0.60%
cases:8.26%
controls:3.43%
cases:13.87%
controls:6.52%
67
283
281
3197
37
123
311
3357
—
—
8
21
340
3454
28
116
311
3262
38
177
236
2537
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
Z03.5 [45590692]
1.6e+00
1.8e+00
—
—
—
2.3e+00
1.3e+00
cases:3.74%
controls:0.78%
cases:1.44%
controls:0.23%
—
—
—
—
—
—
cases:2.65%
controls:0.27%
cases:3.65%
controls:1.03%
13
27
335
3453
5
8
343
3472
—
—
—
9
9
330
3369
10
28
264
2686
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
7.2e-01
9.9e-01
1.1e+00
—
1.7e+00
5.9e-01
5.2e-01
cases:24.43%
controls:13.62%
cases:14.94%
controls:6.15%
cases:2.87%
controls:1.01%
—
—
cases:3.74%
controls:0.72%
cases:9.44%
controls:5.48%
cases:25.18%
controls:16.69%
85
474
263
3006
52
214
296
3266
10
35
338
3445
—
13
25
335
3450
32
185
307
3193
69
453
205
2261
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
8.8e-01
1.0e+00
—
—
1.4e+00
9.8e-01
1.0e+00
cases:14.37%
controls:6.49%
cases:7.76%
controls:2.93%
—
—
—
—
cases:1.44%
controls:0.35%
cases:6.78%
controls:2.66%
cases:15.33%
controls:6.19%
50
226
298
3254
27
102
321
3378
—
—
5
12
343
3463
23
90
316
3288
42
168
232
2546
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
6.7e-01
7.3e-01
1.3e+00
—
9.8e-01
5.7e-01
6.7e-01
cases:35.06%
controls:21.67%
cases:19.54%
controls:10.49%
cases:5.46%
controls:1.61%
—
—
cases:3.16%
controls:1.21%
cases:15.93%
controls:9.71%
cases:37.59%
controls:23.62%
122
754
226
2726
68
365
280
3115
19
56
329
3424
—
11
42
337
3433
54
328
285
3050
103
641
171
2073
Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum
17791-5 [3027450]
17791-5 [3027450]
1.5e+00
2.3e+00
—
—
—
1.4e+00
1.1e+00
cases:2.87%
controls:0.63%
cases:2.59%
controls:0.26%
—
—
—
—
—
—
cases:1.47%
controls:0.38%
cases:2.92%
controls:0.96%
10
22
338
3458
9
9
339
3471
—
—
—
5
13
334
3365
8
26
266
2688
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
1.1e+00
8.7e-01
1.3e+00
—
1.4e+00
9.3e-01
9.2e-01
cases:21.26%
controls:8.22%
cases:10.06%
controls:4.48%
cases:2.59%
controls:0.69%
—
—
cases:2.01%
controls:0.52%
cases:9.73%
controls:4.09%
cases:22.99%
controls:10.65%
74
286
274
3194
35
156
313
3324
9
24
339
3456
—
7
18
341
3457
33
138
306
3240
63
289
211
2425
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
2.1e+00
1.7e+00
—
—
—
—
8.9e-01
cases:6.90%
controls:0.92%
cases:3.45%
controls:0.63%
—
—
—
—
—
—
—
—
cases:2.92%
controls:1.22%
24
32
324
3448
12
22
336
3458
—
—
—
—
8
33
266
2681
Smith extractable nuclear Ab [Units/volume] in Serum
11090-8 [3016921]
11090-8 [3016921]
1.4e+00
2.3e+00
—
—
—
1.3e+00
1.4e+00
cases:2.59%
controls:0.63%
cases:2.59%
controls:0.26%
—
—
—
—
—
—
cases:1.47%
controls:0.41%
cases:3.65%
controls:0.92%
9
22
339
3458
9
9
339
3471
—
—
—
5
14
334
3364
10
25
264
2689
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
1.7e+00
2.0e+00
—
—
—
1.3e+00
1.1e+00
cases:4.60%
controls:0.83%
cases:3.74%
controls:0.55%
—
—
—
—
—
—
cases:1.77%
controls:0.47%
cases:4.38%
controls:1.47%
16
29
332
3451
13
19
335
3461
—
—
—
6
16
333
3362
12
40
262
2674
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
8.2e-01
1.1e+00
—
—
1.5e+00
9.1e-01
9.0e-01
cases:13.51%
controls:6.44%
cases:7.47%
controls:2.70%
—
—
—
—
cases:1.44%
controls:0.32%
cases:6.49%
controls:2.72%
cases:14.23%
controls:6.30%
47
224
301
3256
26
94
322
3386
—
—
5
11
343
3464
22
92
317
3286
39
171
235
2543
No procedures
SPAT1301 [2001700402]
SPAT1301 [2001700402]
7.0e-01
6.6e-01
2.2e+00
—
—
7.2e-02
8.1e-01
cases:12.64%
controls:6.72%
cases:4.31%
controls:2.27%
cases:2.01%
controls:0.23%
—
—
—
—
cases:2.06%
controls:1.92%
cases:9.85%
controls:4.64%
44
234
304
3246
15
79
333
3401
7
8
341
3472
—
—
7
65
332
3313
27
126
247
2588
Ehlers-Danlos syndrome
Q79.6 [45587483]
Q79.6 [45587483]
—
—
—
1.0e+50
—
3.7e+00
—
—
—
—
—
—
—
cases:3.45%
controls:0.00%
—
—
cases:5.60%
controls:0.15%
—
—
—
—
—
12
0
336
3480
—
19
5
320
3373
—
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
ZXE06 [2001311400]
1.6e+00
—
—
—
—
—
2.0e+00
cases:4.31%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.59%
15
30
333
3450
—
—
—
—
—
12
16
262
2698
naproxcinod
M01AE18 [40254094]
M01AE18 [40254094]
8.7e-01
9.4e-01
—
—
—
9.4e-01
9.3e-01
cases:23.28%
controls:11.32%
cases:10.92%
controls:4.57%
—
—
—
—
—
—
cases:9.73%
controls:4.03%
cases:21.53%
controls:9.80%
81
394
267
3086
38
159
310
3321
—
—
—
33
136
306
3242
59
266
215
2448
naproxen; oral, rectal
M01AE02 [21603968]
M01AE02 [21603968]
8.7e-01
9.4e-01
—
—
—
9.4e-01
9.3e-01
cases:23.28%
controls:11.32%
cases:10.92%
controls:4.57%
—
—
—
—
—
—
cases:9.73%
controls:4.03%
cases:21.53%
controls:9.80%
81
394
267
3086
38
159
310
3321
—
—
—
33
136
306
3242
59
266
215
2448
Abdominal pain epigastric
D02 [2002000301]
D02 [2002000301]
1.4e+00
—
—
—
—
2.3e+00
1.1e+00
cases:3.16%
controls:0.83%
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.18%
cases:2.55%
controls:0.88%
11
29
337
3451
—
—
—
—
6
6
333
3372
7
24
267
2690
C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 [3010156]
30522-7 [3010156]
1.7e-01
1.1e+00
—
—
—
1.9e+00
1.8e+00
cases:1.72%
controls:1.47%
cases:1.72%
controls:0.57%
—
—
—
—
—
—
cases:3.83%
controls:0.59%
cases:7.66%
controls:1.40%
6
51
342
3429
6
20
342
3460
—
—
—
13
20
326
3358
21
38
253
2676
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
K21.9 [45538509]
1.5e+00
2.1e+00
—
—
—
1.4e+00
1.1e+00
cases:4.60%
controls:1.09%
cases:2.87%
controls:0.34%
—
—
—
—
—
—
cases:1.47%
controls:0.36%
cases:3.28%
controls:1.14%
16
38
332
3442
10
12
338
3468
—
—
—
5
12
334
3366
9
31
265
2683
Monitoring the use of the aid
R5140 [2001310249]
R5140 [2001310249]
1.1e+00
1.3e+00
—
—
—
2.2e+00
1.4e+00
cases:2.87%
controls:1.01%
cases:2.01%
controls:0.55%
—
—
—
—
—
—
cases:2.06%
controls:0.24%
cases:4.74%
controls:1.18%
10
35
338
3445
7
19
341
3461
—
—
—
7
8
332
3370
13
32
261
2682
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
7.4e-01
1.0e+00
-1.0e+50
—
-1.0e+50
1.5e+00
1.4e+00
cases:10.92%
controls:5.52%
cases:3.74%
controls:1.35%
cases:0.00%
controls:0.17%
—
—
cases:0.00%
controls:0.20%
cases:5.31%
controls:1.21%
cases:8.03%
controls:2.21%
38
192
310
3288
13
47
335
3433
0
6
348
3474
—
0
7
348
3468
18
41
321
3337
22
60
252
2654
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
9.2e-01
9.6e-01
—
—
1.1e+00
9.3e-01
7.9e-01
cases:12.07%
controls:5.17%
cases:6.32%
controls:2.53%
—
—
—
—
cases:1.44%
controls:0.49%
cases:5.31%
controls:2.16%
cases:10.58%
controls:5.08%
42
180
306
3300
22
88
326
3392
—
—
5
17
343
3458
18
73
321
3305
29
138
245
2576
Anxiety disorder, unspecified
F41.9 [45542849]
F41.9 [45542849]
9.2e-01
1.2e+00
2.0e+00
—
1.8e+00
1.4e+00
6.6e-01
cases:6.32%
controls:2.61%
cases:4.02%
controls:1.21%
cases:1.44%
controls:0.20%
—
—
cases:1.72%
controls:0.29%
cases:5.60%
controls:1.42%
cases:9.49%
controls:5.12%
22
91
326
3389
14
42
334
3438
5
7
343
3473
—
6
10
342
3465
19
48
320
3330
26
139
248
2575
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
1.2e+00
1.4e+00
—
—
—
1.2e-01
9.2e-01
cases:8.33%
controls:2.56%
cases:5.17%
controls:1.32%
—
—
—
—
—
—
cases:1.77%
controls:1.57%
cases:7.66%
controls:3.21%
29
89
319
3391
18
46
330
3434
—
—
—
6
53
333
3325
21
87
253
2627
amitriptyline and psycholeptics
N06CA01 [21604789]
N06CA01 [21604789]
1.4e+00
2.2e+00
—
—
—
1.7e+00
1.4e+00
cases:4.60%
controls:1.18%
cases:3.16%
controls:0.37%
—
—
—
—
—
—
cases:1.47%
controls:0.27%
cases:3.28%
controls:0.81%
16
41
332
3439
11
13
337
3467
—
—
—
5
9
334
3369
9
22
265
2692
lisdexamfetamine; oral
N06BA12 [40252237]
N06BA12 [40252237]
—
1.5e+00
—
—
—
1.9e+00
1.6e+00
—
—
cases:1.72%
controls:0.37%
—
—
—
—
—
—
cases:2.65%
controls:0.41%
cases:4.01%
controls:0.81%
—
6
13
342
3467
—
—
—
9
14
330
3364
11
22
263
2692
Acetylcholine receptor Ab [Moles/volume] in Serum
20427-1 [3006257]
20427-1 [3006257]
3.5e+00
1.0e+50
—
—
—
—
—
cases:4.60%
controls:0.14%
cases:3.74%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
16
5
332
3475
13
0
335
3480
—
—
—
—
—
Nausea and vomiting
R11 [45539317]
R11 [45539317]
1.8e+00
1.4e+00
—
—
—
1.6e+00
1.7e+00
cases:4.31%
controls:0.75%
cases:1.72%
controls:0.43%
—
—
—
—
—
—
cases:1.47%
controls:0.30%
cases:5.84%
controls:1.11%
15
26
333
3454
6
15
342
3465
—
—
—
5
10
334
3368
16
30
258
2684
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
8.0e-01
1.4e+00
—
—
—
9.4e-01
1.2e+00
cases:10.34%
controls:4.94%
cases:6.61%
controls:1.64%
—
—
—
—
—
—
cases:3.83%
controls:1.54%
cases:13.50%
controls:4.31%
36
172
312
3308
23
57
325
3423
—
—
—
13
52
326
3326
37
117
237
2597
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
SPAT1230 [2001700331]
9.6e-01
1.7e+00
—
—
—
1.4e+00
1.8e+00
cases:4.60%
controls:1.81%
cases:2.59%
controls:0.49%
—
—
—
—
—
—
cases:2.06%
controls:0.53%
cases:6.93%
controls:1.22%
16
63
332
3417
9
17
339
3463
—
—
—
7
18
332
3360
19
33
255
2681
Palpitations
R00.2 [45558446]
R00.2 [45558446]
1.6e+00
1.9e+00
—
—
—
1.1e+00
1.2e+00
cases:5.75%
controls:1.26%
cases:2.87%
controls:0.43%
—
—
—
—
—
—
cases:1.77%
controls:0.59%
cases:4.01%
controls:1.25%
20
44
328
3436
10
15
338
3465
—
—
—
6
20
333
3358
11
34
263
2680
Moderate depressive episode
F32.1 [45552478]
F32.1 [45552478]
1.5e+00
1.0e+00
—
—
—
2.0e+00
8.6e-01
cases:5.75%
controls:1.32%
cases:2.01%
controls:0.72%
—
—
—
—
—
—
cases:2.65%
controls:0.38%
cases:4.01%
controls:1.73%
20
46
328
3434
7
25
341
3455
—
—
—
9
13
330
3365
11
47
263
2667
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
AA1CG [2001300116]
1.8e+00
1.7e+00
—
—
—
—
1.3e+00
cases:5.46%
controls:0.98%
cases:2.30%
controls:0.43%
—
—
—
—
—
—
—
—
cases:2.55%
controls:0.70%
19
34
329
3446
8
15
340
3465
—
—
—
—
7
19
267
2695
3-Methoxytyramine [Moles/volume] in Serum or Plasma
50140-3 [3030408]
50140-3 [3030408]
3.5e+00
—
—
—
—
1.0e+50
—
cases:5.17%
controls:0.17%
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.00%
—
—
18
6
330
3474
—
—
—
—
8
0
331
3378
—
Normetanephrine [Moles/volume] in Serum or Plasma
25489-6 [3026179]
25489-6 [3026179]
3.5e+00
—
—
—
—
1.0e+50
2.0e+00
cases:5.17%
controls:0.17%
—
—
—
—
—
—
—
—
cases:2.65%
controls:0.00%
cases:1.82%
controls:0.26%
18
6
330
3474
—
—
—
—
9
0
330
3378
5
7
269
2707
Ambulatory ECG
XF404 [2001303370]
XF404 [2001303370]
1.6e+00
—
—
—
—
—
1.8e+00
cases:4.02%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:2.92%
controls:0.48%
14
29
334
3451
—
—
—
—
—
8
13
266
2701
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
204
295
15.30
152.93
2.6
1.9
386.22
376.44
nmol/l
0.29
195
278
171
230
13.65
133.00
2.9
2.3
30.62
17.63
au/ml
—
9
29
83
84
12.66
75.92
1.3
1.4
258.05
170.03
u/ml
2.34
59
51
118
236
7.05
60.85
3.0
2.5
10.02
10.31
g/l
0.46
107
227
249
1020
6.07
56.20
2.4
1.8
99.58
96.28
pmol/l
0.49
145
586
128
300
6.17
55.54
2.8
2.4
28.52
24.14
%
3.36
121
281
141
367
5.78
54.35
3.1
2.3
16.67
14.33
umol/l
3.74
133
343
132
334
5.76
52.29
3.0
2.3
2.45
2.46
g/l
0.07
127
306
237
983
5.42
51.14
5.1
6.5
1.22
1.22
mmol/l
0.08
229
919
253
1135
5.50
48.66
5.7
6.5
1.22
1.21
mmol/l
0.13
225
994
271
1313
5.81
46.54
3.5
2.6
76.89
72.58
nmol/l
1.73
263
1248
76
129
7.26
45.04
1.9
1.3
—
—
—
0
0
145
458
4.71
42.84
1.8
1.6
453.98
64048035.28
pmol/l
1.04
137
420
41
36
12.78
40.31
1.7
1.4
23.04
30.30
ng/l
0.33
41
36
169
631
4.26
39.31
1.8
1.5
20.75
20.85
nmol/l
0.02
159
577
220
997
4.28
38.73
3.9
4.8
38.27
37.54
g/l
1.54
210
956
121
358
4.65
38.35
2.9
3.6
0.84
0.82
mmol/l
1.39
113
342
51
66
8.88
38.03
1.3
1.8
13.51
75.20
e6/l
0.90
41
51
196
836
4.08
37.25
2.3
2.8
2.33
2.35
mmol/l
1.46
184
786
50
65
8.82
37.12
1.2
1.8
1.03
16.52
e6/l
0.79
38
48
35
27
14.30
37.10
1.2
1.2
23.70
29.60
mg/l
0.59
30
21
113
331
4.57
36.04
1.7
1.3
82.72
149.11
u/ml
1.68
45
144
64
114
6.65
35.86
1.8
1.1
3.63
4.55
—
9
22
302
1785
6.23
35.78
6.0
3.3
82.79
69.02
ug/l
1.19
296
1719
291
1712
5.27
33.52
8.8
9.6
3.84
3.92
e9/l
0.29
269
1511
81
195
5.11
32.68
2.5
4.2
188.71
235.64
u/l
4.07
75
195
35
36
10.70
30.83
1.5
2.0
5.07
5.12
kpa
0.12
35
36
33
33
10.94
29.61
1.1
1.1
—
—
—
0
0
94
277
4.28
29.18
1.6
1.3
131.21
174.28
u/ml
0.28
88
252
251
1431
3.71
27.68
4.5
4.9
5.75
6.26
mmol/l
6.75
235
1290
32
34
10.26
27.48
1.1
1.1
—
—
—
0
0
157
676
3.41
27.45
3.1
2.5
0.09
0.28
e6/l
3.13
121
485
182
858
3.35
27.37
2.2
1.4
1.87
2.10
g/l
2.04
136
575
134
540
3.41
25.81
2.2
2.9
40.58
85.80
ug/g
6.26
101
429
32
39
8.93
24.77
1.6
1.3
0.15
0.15
nmol/l
0.01
26
28
63
155
4.74
24.40
1.9
2.2
2.36
5.29
iu/ml
1.46
18
28
91
295
3.82
24.36
1.8
1.5
1163.51
1089.24
nmol/l
0.31
73
237
29
32
9.80
24.18
1.0
1.1
—
—
—
0
0
125
509
3.27
23.31
2.6
2.3
4.29
9.59
e6/l
2.43
114
461
109
409
3.42
23.23
2.1
2.1
2.39
2.41
mmol/l
0.59
93
363
162
783
3.00
22.19
3.6
2.7
25.63
20.30
ng/l
0.16
59
327
151
713
2.97
21.42
3.2
2.3
2.14
2.59
mg/l
3.69
135
631
101
382
3.32
21.02
2.6
2.4
3.10
3.74
e6/l
0.26
56
178
225
1332
2.95
20.65
5.2
5.7
9.40
10.18
umol/l
1.08
215
1278
183
972
2.86
20.65
1.7
1.4
2.08
1.90
u/ml
0.04
63
279
247
1547
3.06
20.25
4.4
3.1
0.07
4.67
estimate
0.49
71
323
248
1559
3.06
20.15
4.4
3.2
0.00
0.00
estimate
-0.00
73
311
245
1539
3.00
19.76
4.3
3.1
0.00
0.00
estimate
0.50
72
319
52
131
4.49
19.39
2.0
9.9
25.20
25.04
mmol/l
0.14
52
131
31
21
16.08
19.32
1.3
1.1
0.48
0.56
ratio
1.64
21
11
40
83
5.32
18.76
1.6
1.1
7.58
16.38
au/ml
1.02
13
33
328
2508
6.36
18.41
7.8
4.5
14.49
14.26
pmol/l
1.17
323
2378
190
1081
2.67
17.98
3.5
3.2
23.86
27.66
u/l
2.10
185
1042
98
397
3.04
17.85
2.3
3.1
683.27
440.54
ng/l
0.24
74
321
339
2852
8.29
17.23
9.5
5.3
1.61
1.71
mu/l
1.30
334
2748
55
158
3.95
17.17
2.6
1.8
—
—
—
0
0
27
18
16.15
16.96
1.8
3.3
356.59
429.00
u/ml
0.56
27
18
24
12
21.37
16.66
1.5
1.1
119.25
185.17
mmol/24h
1.91
24
12
34
68
5.43
16.56
1.3
1.1
1.21
1.66
—
8
19
137
691
2.62
16.21
2.3
2.0
0.36
0.78
mg/l
3.98
92
515
137
699
2.58
15.74
1.5
1.3
363.17
22.64
iu/ml
0.49
29
201
27
25
11.61
14.77
1.1
1.1
—
—
—
0
0
27
49
5.89
14.54
1.2
2.3
2.73
2.72
g/l
0.01
27
49
165
944
2.42
14.53
3.5
2.5
0.78
0.03
estimate
0.47
64
267
146
795
2.44
14.31
4.3
3.2
0.00
0.01
estimate
1.08
73
318
61
211
3.29
14.31
2.4
2.9
0.25
0.23
g/l
1.47
56
204
194
1199
2.40
14.25
4.0
2.9
0.00
0.03
estimate
0.96
63
276
27
50
5.77
14.24
1.2
2.3
6.61
6.87
g/l
0.43
27
50
27
50
5.77
14.24
1.2
2.3
3.77
3.48
g/l
0.26
27
50
27
50
5.77
14.24
1.2
2.3
4.74
4.47
g/l
0.19
27
50
133
699
2.46
14.04
3.5
2.9
1.02
1.02
kg/l
2.14
98
452
22
34
6.84
13.81
1.1
1.3
—
—
—
0
0
322
2571
4.38
13.71
5.4
4.3
35.57
36.99
mmol/mol
3.22
317
2483
124
644
2.44
13.32
1.5
1.3
1.31
9.41
u/ml
2.22
48
271
88
393
2.66
12.95
1.7
1.4
22.02
21.77
iu/l
0.03
77
342
86
380
2.68
12.92
3.3
2.8
106.72
249.86
ng/l
0.83
29
193
21
34
6.51
12.62
1.1
1.2
—
—
—
0
0
30
69
4.66
12.42
1.4
1.4
341.50
354.22
ug/g
0.08
14
38
68
286
2.71
11.14
2.2
2.9
29.57
29.92
s
0.26
68
281
86
412
2.44
10.75
2.7
2.3
0.52
0.84
e6/l
1.04
44
206
21
40
5.52
10.72
1.2
2.3
9.43
10.02
g/l
0.37
21
40
22
26
8.95
10.71
1.4
1.6
—
—
—
0
0
38
120
3.43
10.21
1.1
1.1
2.40
6.77
u/ml
1.50
23
69
49
185
2.92
9.78
2.0
1.8
3.99
3.26
mg/l
0.30
39
129
20
40
5.24
9.69
1.2
2.3
0.00
0.00
g/l
-0.00
20
35
48
182
2.90
9.50
1.4
1.4
—
—
—
0
0
339
3048
5.34
9.48
20.9
10.8
15.29
19.25
mg/l
1.82
287
2399
17
16
11.10
9.39
1.8
2.4
2.28
1.91
nmol/l
0.21
17
16
46
172
2.93
9.33
1.4
1.4
11.75
10.32
u/l
0.20
35
139
326
2778
3.74
9.30
15.8
8.9
96.61
95.60
ml/min/173m2
0.47
306
2489
48
185
2.85
9.22
3.2
2.1
13.58
12.74
nmol/l
0.26
43
177
46
179
2.81
8.67
4.2
5.8
2.15
1.60
mmol/l
0.62
40
153
21
33
6.70
8.62
1.1
1.2
—
—
—
0
0
21
33
6.70
8.62
1.1
1.2
—
—
—
0
0
21
33
6.70
8.62
1.1
1.2
—
—
—
0
0
20
31
6.78
8.31
1.2
1.2
—
—
—
0
0
17
21
8.45
8.18
1.2
1.0
0.94
1.02
u/l
—
7
10
20
32
6.56
8.14
2.4
5.5
151.06
48.27
u/ml
—
5
11
20
47
4.45
8.05
1.2
1.1
8.54
12.12
u/ml
—
9
26
19
29
6.86
8.00
1.3
2.1
18.81
17.42
%
1.39
19
29
37
134
2.97
7.93
1.5
1.5
0.26
0.36
nmol/l
1.47
31
113
317
2713
2.89
7.87
4.8
3.5
5.50
5.60
mmol/l
0.90
307
2585
34
118
3.09
7.84
3.6
6.9
23.50
24.09
mmol/l
0.47
34
118
12
8
15.47
7.77
1.1
1.0
—
—
—
0
0
22
58
3.98
7.65
2.0
4.5
9.50
8.77
kpa
1.21
22
58
11
6
18.87
7.65
1.2
1.0
—
—
—
0
0
11
6
18.87
7.65
1.2
1.2
—
—
—
0
0
51
226
2.47
7.41
1.9
1.5
—
—
—
0
0
43
179
2.60
7.10
1.4
1.7
0.15
0.27
mg/l
—
6
79
65
330
2.19
6.90
1.9
1.6
—
—
—
0
0
31
110
3.00
6.88
1.8
3.6
1.87
0.97
mmol/l
0.71
21
82
12
12
10.31
6.58
1.1
1.2
67.23
75.42
nmol/24h
0.17
12
12
36
144
2.67
6.43
1.3
1.6
—
—
—
0
0
9
5
18.42
6.29
1.1
1.4
—
—
—
0
0
9
5
18.42
6.29
1.1
1.6
—
—
—
0
0
9
5
18.42
6.29
1.0
1.2
—
—
—
0
0
278
2320
1.99
6.18
4.0
3.2
29.12
33.36
u/l
1.22
273
2251
31
118
2.79
6.08
1.2
1.1
0.80
1.50
u/ml
0.48
15
57
49
235
2.26
5.94
2.0
1.5
—
—
—
0
0
54
270
2.18
5.92
3.5
2.4
29.96
31.96
u/l
0.21
49
226
22
71
3.24
5.72
1.2
1.3
—
—
—
0
0
18
52
3.60
5.53
1.1
1.5
—
—
—
0
0
18
54
3.46
5.24
2.7
2.2
0.29
1.97
index
—
7
26
94
595
1.79
5.20
2.0
2.3
292.25
305.03
umol/l
0.77
85
561
61
338
1.98
5.08
2.0
2.8
4.30
5.86
umol/l
0.97
50
292
48
244
2.12
5.04
6.5
7.6
104.02
104.75
mmol/l
0.63
48
244
85
527
1.81
5.02
1.8
1.9
1.37
1.32
%
0.44
78
494
148
1072
1.66
5.00
2.2
1.8
—
—
—
0
0
32
139
2.43
4.85
1.2
1.1
0.16
3.13
u/ml
2.89
16
77
23
87
2.76
4.59
1.2
1.1
0.01
0.32
u/ml
—
5
25
26
105
2.60
4.58
1.2
1.0
0.55
3.58
u/ml
1.83
11
46
15
44
3.52
4.52
1.3
2.4
4.82
6.77
pmol/l
1.02
15
44
12
23
5.36
4.49
1.1
1.0
135.42
120.09
pmol/l
0.44
12
23
14
32
4.51
4.49
1.1
2.0
518.00
549.37
e6/l
—
8
24
14
33
4.38
4.37
1.1
1.8
269.25
230.19
e6/l
—
8
26
26
108
2.52
4.34
1.7
1.4
—
—
—
0
0
21
78
2.80
4.33
1.0
1.1
3.01
2.18
eliau/ml
—
7
40
10
17
6.02
4.16
1.1
1.1
—
—
—
0
0
15
48
3.22
3.98
1.3
1.2
—
—
—
0
0
22
89
2.57
3.88
1.7
2.4
205.63
93.42
ng/l
0.34
16
78
8
11
7.41
3.88
1.0
1.0
—
—
—
0
0
14
45
3.20
3.69
1.0
1.1
—
—
—
0
0
27
125
2.26
3.58
1.6
2.4
2.41
4.69
iu/l
—
9
56
11
26
4.33
3.53
1.2
1.1
161.23
172.42
iu/ml
0.07
11
26
15
52
2.97
3.51
1.7
2.3
142.47
133.95
g/l
1.40
15
42
22
94
2.43
3.49
1.2
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
14
5.82
3.36
1.4
1.3
—
—
—
0
0
10
24
4.26
3.22
1.3
1.8
1.84
1.65
mmol/l
—
10
24
8
15
5.43
3.21
1.5
1.3
—
—
—
0
0
21
93
2.34
3.10
1.1
1.2
—
—
—
0
0
54
337
1.71
3.07
2.3
2.1
1301.38
5856.72
u/l
1.86
18
142
120
911
1.48
2.96
2.3
2.2
—
—
—
0
0
14
52
2.76
2.92
1.1
1.3
—
—
—
0
0
27
137
2.05
2.89
2.0
1.8
16.51
6.39
u/ml
—
8
39
24
117
2.13
2.84
1.3
1.5
0.03
0.04
iu/ml
—
9
18
19
85
2.31
2.75
6.4
3.5
48.31
51.94
%
0.23
19
85
16
66
2.49
2.75
1.3
1.3
4.55
3.80
u/ml
0.13
11
30
11
34
3.31
2.75
1.6
3.3
16.61
16.48
mu/l
0.01
11
34
8
19
4.28
2.69
1.8
1.8
—
—
—
0
0
9
24
3.82
2.69
1.3
1.1
53.36
55.21
u/ml
—
9
24
16
67
2.45
2.67
1.3
1.2
2.50
4.22
u/ml
—
8
27
31
171
1.89
2.64
8.4
11.7
1.47
0.88
mmol/l
0.36
23
144
14
312
0.43
2.64
1.4
1.5
—
—
—
0
0
110
838
1.46
2.62
2.2
2.1
—
—
—
0
0
9
25
3.67
2.59
1.7
1.5
—
—
—
0
0
9
25
3.67
2.59
1.0
1.1
2745.22
1521.24
miu/ml
—
9
25
13
50
2.66
2.56
1.5
1.3
—
—
—
0
0
13
50
2.66
2.56
1.5
1.3
—
—
—
0
0
5
7
7.23
2.55
1.0
1.3
—
—
—
0
0
5
7
7.23
2.55
1.2
1.3
—
—
—
0
0
5
7
7.23
2.55
1.0
1.0
—
—
—
0
0
311
2892
1.71
2.48
4.4
3.8
1.46
1.48
mmol/l
0.46
300
2788
17
76
2.30
2.48
1.6
1.6
—
—
—
0
0
31
175
1.85
2.47
2.8
2.2
83.47
81.72
ml/min/173m2
0.10
19
74
16
70
2.35
2.45
1.2
1.1
—
—
—
0
0
11
38
2.96
2.43
1.7
2.1
—
—
—
0
0
11
38
2.96
2.43
1.5
1.3
—
—
—
0
0
144
1166
1.40
2.42
1.9
1.8
1.38
1.39
mmol/l
0.01
127
1062
8
22
3.70
2.38
1.3
1.6
5.02
5.43
mmol/l
—
8
22
311
2899
1.68
2.37
4.6
3.9
4.79
4.79
mmol/l
0.02
301
2804
111
863
1.42
2.34
1.9
1.6
—
—
—
0
0
312
2913
1.69
2.33
4.9
4.1
2.93
2.88
mmol/l
0.54
302
2815
20
99
2.08
2.31
5.1
5.5
0.52
0.60
%
0.62
20
99
12
267
0.43
2.27
1.2
1.5
1.20
1.12
ratio
—
7
171
12
267
0.43
2.27
1.2
1.5
1.13
1.15
ratio
—
7
171
12
267
0.43
2.27
1.2
1.5
0.75
0.93
ratio
—
7
171
36
219
1.72
2.26
6.5
4.1
—
—
—
0
0
12
264
0.44
2.21
1.2
1.5
—
—
—
0
0
5
10
5.05
2.07
1.0
1.0
—
—
—
0
0
7
20
3.55
2.06
1.0
2.1
—
0.99
—
0
6
6
15
4.05
2.04
1.3
1.5
—
—
—
0
0
6
15
4.05
2.04
1.3
1.5
—
—
—
0
0
38
242
1.64
2.03
1.1
1.0
—
—
—
0
0
6
17
3.57
1.84
1.2
1.1
—
—
—
0
0
5
12
4.21
1.83
3.8
3.0
—
—
—
0
0
5
12
4.21
1.83
3.2
3.3
140.40
115.00
%
—
5
12
8
31
2.62
1.67
1.3
1.3
—
—
—
0
0
8
32
2.53
1.60
1.3
1.3
—
—
—
0
0
6
20
3.03
1.58
1.2
1.7
—
—
—
0
0
8
33
2.46
1.54
1.3
1.2
—
—
—
0
0
8
33
2.46
1.54
1.1
1.3
—
—
—
0
0
17
93
1.87
1.54
2.3
1.5
—
—
—
0
0
65
494
1.39
1.53
2.1
1.9
—
—
—
0
0
5
16
3.15
1.44
1.4
1.1
98.18
186.62
pmol/l
—
5
16
9
39
2.34
1.44
1.3
1.4
—
—
—
0
0
11
53
2.11
1.40
1.1
1.4
—
—
—
0
0
75
595
1.33
1.35
2.0
2.1
—
—
—
0
0
12
62
1.97
1.29
1.0
1.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
5
18
2.80
1.29
1.0
1.0
117.00
136.78
%
—
5
18
8
35
2.32
1.27
1.3
1.1
—
—
—
0
0
29
196
1.52
1.26
1.7
1.6
—
—
—
0
0
6
25
2.42
1.25
2.0
1.5
54.00
70.36
umol/l
—
6
25
28
189
1.52
1.23
3.3
2.4
—
—
—
0
0
288
2724
1.33
1.22
3.9
3.3
1.23
1.21
mmol/l
0.17
276
2610
8
37
2.19
1.22
1.4
1.1
26.91
34.12
nmol/l
—
8
27
22
142
1.59
1.17
3.9
4.5
2.13
8.83
ug/l
2.09
17
108
7
32
2.21
1.08
1.3
1.3
—
—
—
0
0
7
32
2.21
1.08
1.3
1.3
—
—
—
0
0
7
32
2.21
1.08
1.3
1.3
—
—
—
0
0
24
162
1.52
1.07
1.2
1.4
—
—
—
0
0
7
33
2.14
1.06
1.3
1.2
—
—
—
0
0
7
33
2.14
1.06
1.3
1.2
—
—
—
0
0
5
22
2.29
1.03
1.2
1.1
6.20
7.77
mm/h
—
5
22
13
213
0.60
1.03
1.1
1.1
1.65
1.56
g/l
0.54
13
213
17
108
1.60
0.98
1.4
1.6
—
—
—
0
0
28
200
1.44
0.97
2.1
1.9
22.65
35.84
u/ml
0.69
28
192
10
55
1.84
0.93
1.2
1.5
7.08
7.35
mmol/l
—
10
48
8
42
1.93
0.89
1.1
1.3
—
—
—
0
0
14
216
0.63
0.89
1.1
1.1
0.91
0.89
g/l
0.16
14
216
6
30
2.02
0.87
1.2
1.3
—
—
—
0
0
6
31
1.95
0.85
1.0
2.6
—
—
—
0
0
6
31
1.95
0.85
1.2
2.1
0.94
0.79
e9/l
—
6
31
5
26
1.94
0.71
1.8
1.3
—
—
—
0
0
10
61
1.66
0.69
1.2
1.5
—
—
—
0
0
9
59
1.54
0.69
5.6
3.0
8.00
528.54
u/ml
—
9
52
5
27
1.86
0.68
1.2
1.4
—
—
—
0
0
76
663
1.19
0.63
1.9
2.1
—
—
—
0
0
8
49
1.65
0.62
1.1
1.3
—
—
—
0
0
279
2690
1.19
0.61
5.0
3.9
—
—
—
0
0
9
60
1.51
0.54
1.0
1.4
—
—
—
0
0
66
581
1.17
0.50
3.2
3.9
22.55
10.52
mg/mmol
0.32
41
379
29
236
1.25
0.48
1.2
1.4
—
—
—
0
0
18
141
1.29
0.41
2.6
2.0
0.57
0.65
ug/l
—
10
51
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
5
35
1.43
0.39
1.2
1.5
—
—
—
0
0
23
188
1.24
0.38
2.5
2.7
21.82
21.72
%
—
8
46
6
45
1.34
0.34
2.0
1.6
6.30
7.59
mmol/l
—
6
45
6
90
0.66
0.33
1.3
1.4
—
—
—
0
0
11
83
1.34
0.32
2.1
2.0
—
—
—
0
0
10
77
1.31
0.26
1.8
1.8
—
—
—
0
0
19
162
1.18
0.23
1.2
1.6
73.45
53.61
ug/l
1.19
19
162
19
220
0.86
0.22
1.4
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
12
0.00
0.21
0.0
14.0
—
38.14
—
0
7
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
57.08
—
0
13
19
164
1.17
0.21
2.3
1.9
—
—
—
0
0
16
187
0.85
0.20
1.6
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
7
63
1.11
0.17
1.6
1.1
—
—
—
0
0
142
1377
1.05
0.16
2.5
2.7
—
—
estimate
—
0
0
51
535
0.95
0.11
2.4
1.8
3.25
3.33
ratio
0.17
38
410
44
421
1.05
0.08
2.0
1.6
3.16
3.42
mmol/l
0.77
30
295
17
181
0.94
0.05
1.5
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
4.10
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
2.44
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
7.02
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
23
230
1.00
-0.00
1.3
1.3
247.00
258.82
miu/ml
—
9
115
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.43
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint G6_POSTVIRFAT and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have G6_POSTVIRFAT.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: G6_POSTVIRFAT – Postviral fatigue syndrome
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data